Home Cart Sign in  
Chemical Structure| 231277-92-2 Chemical Structure| 231277-92-2
Chemical Structure| 231277-92-2

Lapatinib

CAS No.: 231277-92-2

Lapatinib (GW572016) demonstrates potent inhibition of the ErbB-2 and EGFR tyrosine kinase domains, with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.

Synonyms: GW572016; GW2016; GSK572016

4.5 *For Research Use Only !

Cat. No.: A254504 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1mg łÇ˶ÊÊ Inquiry Inquiry
50mg ł§Í¶ÊÊ Inquiry Inquiry
100mg łÍ˶ÊÊ Inquiry Inquiry
250mg łÿ§¶ÊÊ Inquiry Inquiry
1g łòͶÊÊ Inquiry Inquiry
5g łÇóî¶ÊÊ Inquiry Inquiry
25g łòÊď¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1mg

    łÇ˶ÊÊ

  • 50mg

    ł§Í¶ÊÊ

  • 100mg

    łÍ˶ÊÊ

  • 250mg

    łÿ§¶ÊÊ

  • 1g

    łòͶÊÊ

  • 5g

    łÇóî¶ÊÊ

  • 25g

    łòÊď¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Product Citations      Show More

Soniya Kumbham ; Kazi Md Mahabubur Rahman ; Caroline Bosmajian ; Ganesh Bist ; Barbara A. Foster ; Sukyung Woo , et al.

Abstract: Protoporphyrin IX (PpIX)-based photodynamic therapy (PDT) has shown limited efficacy in nonmuscle-invasive bladder cancer (NMIBC). To improve PDT efficacy, we developed singlet oxygen-cleavable prodrugs. These prodrugs, when combined with PpIX-PDT, induce cancer cell death through both PDT and drug release mechanisms. Inhibition of PpIX efflux was reported to be an effective strategy to improve PpIX-PDT in certain cancer cells. Our main goal was to investigate whether adding an efflux inhibitor to the combination of PpIX and prodrugs can improve the PpIX levels in bladder cancer cells and the release of active drugs, thus improving the overall efficacy of the treatment. We treated bladder cancer cell lines with and evaluated intracellular PpIX fluorescence, finding significantly increased accumulation. Combining with prodrugs led to significantly reduced cell viability compared to prodrugs or PpIX-PDT alone. The effect of depended on the expression level of the efflux pump in bladder cancer cells. Interestingly, increased (PTX) prodrug uptake by threefold compared to prodrug alone. Adding an efflux inhibitor (e.g., lapatinib) into bladder instillation solutions could be a straightforward and effective strategy for NMIBC treatment, particularly in tumors expressing efflux pumps, with the potential for clinical translation.

Purchased from AmBeed:

Uram, Lukasz ; Wrobel, Konrad ; Walczak, Malgorzata ; Szymaszek, Zaneta ; Twardowska, Magdalena ; Wolowiec, Stanislaw

Abstract: Fulvestrant (F), lapatinib (L), and paclitaxel (P) are hydrophobic, anticancer drugs used in the treatment of estrogen receptor (ER) and epidermal growth factor receptor (EGFR)-pos. breast cancer. In this study, glycidylated PAMAM G4 dendrimers, substituted with F, L, and/or P and targeting tumor cells, were synthesized and characterized, and their antitumor activity against glioma U-118 MG and non-small cell lung cancer A549 cells was tested comparatively with human non-tumorogenic keratinocytes (HaCaT). All cell lines were ER+ and EGFR+. In addition, the described drugs were tested in the context of antinematode therapy on C. elegans. The results show that the water-soluble conjugates of G4P, G4F, G4L, and G4PFL actively entered the tested cells via endocytosis due to the pos. zeta potential (between 13.57-40.29 mV) and the nanoparticle diameter of 99-138 nm. The conjugates of G4P and G4PFL at nanomolar concentrations were the most active, and the least active conjugate was G4F. The tested conjugates inhibited the proliferation of HaCaT and A549 cells; in glioma cells, cytotoxicity was associated mainly with cell damage (mitochondria and membrane transport). The toxicity of the conjugates was proportional to the number of drug residues attached, with the exception of G4L; its action was two- and eight-fold stronger against glioma and keratinocytes, resp., than the equivalent of lapatinib alone. Unfortunately, non-cancer HaCaT cells were the most sensitive to the tested constructs, which forced a change in the approach to the use of ER and EGFR receptors as a goal in cancer therapy. In vivo studies on C. elegans have shown that all compounds, most notably G4PFL, may be potentially useful in anthelmintic therapy.

Keywords: paclitaxel ; fulvestrant ; lapatinib ; glycidylated PAMAM G4 dendrimer ; U-118 MG glioma ; A549 NSCLC ; HaCaT keratinocytes ; Caenorhabditis elegans ; proliferation and viability assays ; cellular uptake

Purchased from AmBeed:

Anna Lewińska ; Konrad Wróbel ; Dominika Błoniarz ; Jagoda Adamczyk-Grochala ; Stanisław Wołowiec ; Maciej Wnuk

Abstract: Lapatinib (L) and fulvestrant (F) are used in targeted anticancer therapies, in particular, against phenotypically different breast cancer cells. L, a dual inhibitor of EGFR and HER2 tyrosine kinases, is active against HER2-positive breast cancer cells, while F, a selective estrogen receptor degrader (SERD), is active against ER-positive breast cancer cells. However, the action of L and F can be limited due to their relatively low water solubility and bioavailability. In the present study, poly(amidoamine) (PAMAM) dendrimer G3 was functionalized with L or F or L and F to compare their effects with free L or F against breast cancer cells with different receptor status (ER-positive MCF-7, triple negative MDA-MB-231 and HER2-positive SK-BR-3 cells). L-PAMAM and F-PAMAM conjugates potentiated cytostatic and cytotoxic action of L and F that was accompanied by elevated levels of autophagy. TRDMT1, RNA methyltransferase, was also involved in this response as judged by TRDMT1 nuclear translocation and nano-drug resistance of TRDMT1 gene knockout cells. Nano-drugs also promoted elimination of doxorubicin-induced senescent breast cancer cells by apoptosis-mediated senolysis regardless of receptor status. In conclusion, we propose a novel anticancer approach based on L-PAMAM and F-PAMAM nanoplatforms being effective, at least, against breast cancer cells with different phenotypic features.

Keywords: Lapatinib ; Fulvestrant ; Nano-drugs ; Breast cancer ; Therapy-induced senescence ; Senolysis

Purchased from AmBeed:

Alternative Products

Product Details of Lapatinib

CAS No. :231277-92-2
Formula : C29H26ClFN4O4S
M.W : 581.06
SMILES Code : CS(CCNCC(O1)=CC=C1C2=CC(C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)=NC=N5)=C5C=C2)(=O)=O
Synonyms :
GW572016; GW2016; GSK572016

Safety of Lapatinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of Lapatinib

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR, IC50:10.8 nM

  • HER2/ErbB2

    ErbB2, IC50:9.2 nM

  • ErbB4

    ErbB4, IC50:367 nM

  • HER2

    ErbB2, IC50:9.2 nM

In Vitro:

Cell Line
Concentration Treated Time Description Reference
SKBR3 10 nM 72 h To evaluate the effect of Lapatinib in combination with Trastuzumab on HER2-positive breast cancer cells, results showed cell cycle arrest at G1 and reduced clonogenic potential. PMC6971277
BT474 10 nM 72 h To evaluate the effect of Lapatinib in combination with Trastuzumab on HER2-positive breast cancer cells, results showed cell cycle arrest at G1 and reduced clonogenic potential. PMC6971277
SKBR3 10 nM 72 h To evaluate the effects of dual HER2 blockade on SKBR3 cells, results showed a significant relative increase in Luminal A and normal-like signature scores, and a relative decrease in proliferation, HER2-E, Luminal B and Basal-like signature scores. PMC6971277
BT474 10 nM 72 h To evaluate the effects of dual HER2 blockade on BT474 cells, results showed a significant relative increase in Luminal A and normal-like signature scores, and a relative decrease in proliferation, HER2-E, Luminal B and Basal-like signature scores. PMC6971277
BT474 cells 1 μM 1 h Lapatinib inhibited the phosphorylation of FASN in BT474 cells and suppressed HRG-induced FASN activity. PMC3046439
SKBR3 cells 1 μM 1 h Lapatinib inhibited the phosphorylation of FASN in SKBR3 cells and suppressed HRG-induced FASN activity. PMC3046439
HT-29 colorectal cancer cells 6 μM 24 h To study the inhibitory effect of Sorafenib on the phosphorylation of CSE1L and ERK1/2. The results showed that Sorafenib treatment inhibited ERK1/2 phosphorylation and reduced the levels of hyper- and hypo-phosphorylated CSE1L. PMC4467675

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description Reference
BALB/c-null mice MCF7 tumor model Intravenous injection 2 mg/kg Day 0, 2, 4, 6, for 18 days To evaluate the in vivo anticancer efficacy of LJ@Trp-NPs, the results showed that LJ@Trp-NPs significantly inhibited tumor growth and enhanced the anticancer effect of Lapatinib. PMC8586589
BALB/c-null mice MCF7 tumor model Intravenous injection 2 mg/kg Administered on days 0, 2, 4, and 6, lasting for 18 days To evaluate the synergistic anticancer effect of Lapatinib and JPH203 on MCF7 tumor-bearing mice, results showed significant tumor growth inhibition. PMC8586589
Nude mice SGC031 PDGCX model Oral 100 mg/kg Twice daily for 3 weeks In the SGC031 PDGCX model, Lapatinib did not show significant tumor growth inhibition, with a TGI of 17%. PMC3950883
NOD SCID mice HT-29 colorectal tumor xenograft model Oral 60 mg/kg Once daily for 10 days To study the anti-tumor effect of Lapatinib in the HT-29 colorectal tumor xenograft model. The results showed that Lapatinib treatment significantly inhibited tumor growth and reduced serum phospho-CSE1L levels 3 days after treatment. PMC4467675
NOD/SCID mice MCF-10CA1a-HER2 overexpressing cell model Oral 100 mg/kg Lapatinib, 25 mg/kg BYL719 Once daily for 3 weeks To evaluate the inhibitory effects of Lapatinib and BYL719 alone or in combination on PIK3CAH1047R mutant tumors. The results showed that combination therapy significantly inhibited tumor growth. PMC8567053

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00555152 Ductal Breast Carcinoma In Sit... More >>u HER2/Neu Positive Less << Not Applicable Completed - United States, Alabama ... More >> University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States, 35233 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00555152 - Completed - -
NCT00999804 Breast Cancer Phase 2 Active, not recruiting January 2018 United States, Alabama ... More >> University of Alabama - Birmingham Birmingham, Alabama, United States, 35294 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Maryland Johns Hopkins Baltimore, Maryland, United States, 21231 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02130 United States, North Carolina Duke University Durham, North Carolina, United States, 27705 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37212 United States, Texas Baylor College of Medicine Lester and Sue Smith Breast Center Houston, Texas, United States, 77030 Less <<
NCT00436644 Ovarian Cancer ... More >> Peritoneal Cavity Cancer Less << Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic Arizona Scottsdale, Arizona, United States, 85254 United States, Florida Mayo Clinic in Jacksonville Jacksonville, Florida, United States, 32224 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 Less <<
NCT00436644 - Completed - -
NCT00804310 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Terminated(Lack of funding) - United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010-3000 USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90089-9181 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Louisiana Feist-Weiller Cancer Center at Louisiana State University Health Sciences Shreveport, Louisiana, United States, 71130-3932 Less <<
NCT01619111 HER2-negative Metastatic Breas... More >>t Cancer HER2-positive Circulating Tumor Cells Less << Phase 3 Recruiting March 2020 Germany ... More >> University Hospital Ulm Recruiting Ulm, Baden-Württemberg, Germany, 89075 Principal Investigator: Wolfgang Janni, MD, PhD Less <<
NCT01912963 HER2-positive Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 2 Terminated(The study terminate... More >>d early due to weak accrual.) Less << - United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 Less <<
NCT00999804 - Active, not recruiting - -
NCT02073916 Metastatic Breast Cancer Phase 1 Active, not recruiting December 2018 United States, Texas ... More >> Houston Methodist Hospital Houston, Texas, United States, 77030 Less <<
NCT02139358 Breast Cancer Phase 1 Phase 2 Active, not recruiting December 2019 United States, Florida ... More >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 Less <<
NCT01912963 - Terminated(The study terminate... More >>d early due to weak accrual.) Less << - -
NCT00741260 Breast Cancer Phase 1 Phase 2 Completed - -
NCT02768415 Breast Cancer Phase 2 Active, not recruiting - China, Beijing ... More >> Cancer Institute and Hospital, Chinese Academy of Medical Sciences Beijing, Beijing, China Less <<
NCT00051103 Metastatic Breast Cancer ... More >> Neoplasms, Breast Less << Phase 2 Completed - -
NCT00754702 Breast Cancer Phase 2 Terminated(Poor accrual) - Greece ... More >> University Hospital of Crete, Dep of Medical Oncology Heraklion, Crete, Greece "IASO" General Hospital of Athens, 1st Dep of Medical Oncology Athens, Greece Less <<
NCT00741260 - Completed - -
NCT02029001 Malignant Solid Neoplasms Phase 2 Recruiting October 2022 France ... More >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Antoine ITALIANO    +335 56 33 33 33    a.italiano@bordeaux.unicancer.fr    Principal Investigator: Antoine ITALIANO          Sub-Investigator: Delphine GARBAY          Sub-Investigator: Maud TOULMONDE          Sub-Investigator: Sophie COUSIN          Sub-Investigator: Sylvestre LE MOULEC          Sub-Investigator: Mathilde CABART          Sub-Investigator: Guilhem ROUBAUD          Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France, 63011 Contact: Xavier DURANDO    04 73 27 81 31    xavier.durando@cjp.fr    Principal Investigator: Xavier DURANDO          Sub-Investigator: Pierre DALLOZ          Sub-Investigator: Anne-Françoise DILLIES-LEGRAIN          Sub-Investigator: Pascale DUBRAY-LONGERAS          Sub-Investigator: Hakim MAHAMMEDI          Sub-Investigator: Marie-Ange MOURET-REYNIER          Sub-Investigator: Isabelle VAN PRAAGH DOREAU          Institut Daniel Hollard Not yet recruiting Grenoble, France, 38028 Contact: Cécile LEYRONNAS    04 76 70 73 33    c.leyronnas@ghm-grenoble.fr    Principal Investigator: Cécile LEYRONNAS, MD          Sub-Investigator: Claire GARNIER-TIXIDRE, MD          Sub-Investigator: Laurence LANCRY-LECOMTE, MD          Sub-Investigator: Jérôme LONG, MD          Sub-Investigator: Christine REBISCHUNG, MD          Centre Leon Berard Recruiting Lyon, France, 69373 Contact: Jean-Yves BLAY    +33478785126    jean-yves.blay@lyon.unicancer.fr    Principal Investigator: Jean-Yves BLAY, MD          Sub-Investigator: Virginie AVRILLON          Sub-Investigator: Thomas BACHELOT          Sub-Investigator: Christophe BERGERON          Sub-Investigator: Pierre BIRON          Sub-Investigator: Helen BOYLE          Sub-Investigator: Philippe CASSIER          Sub-Investigator: Patrick COMBEMALE          Sub-Investigator: Maria CHELGHOUM          Sub-Investigator: Françoise DESSEIGNE          Sub-Investigator: Cécile FAURE-CONTER          Sub-Investigator: Jérome FAYETTE          Sub-Investigator: Aude FLECHON          Sub-Investigator: Christelle DE LA FOUCHARDIERE          Sub-Investigator: Didier FRAPPAZ          Sub-Investigator: Pierre GUIBERT          Sub-Investigator: Pierre-Etienne HEUDEL          Sub-Investigator: Eve-Marie NEIDHARDT          Sub-Investigator: Maurice PEROL          Sub-Investigator: Isabelle RAY-COQUARD          Sub-Investigator: Paul REBATTU          Sub-Investigator: Pierre SAINTIGNY          Sub-Investigator: Catherine TERRET          Sub-Investigator: Olivier TREDAN          Sub-Investigator: Olivia BALLY          Sub-Investigator: Stéphane DEPIL          Sub-Investigator: Olfa DERBEL          Sub-Investigator: Nathalie MARQUES          Sub-Investigator: Philippe TOUSSAINT          Sub-Investigator: Mehdi BRAHMI          Sub-Investigator: Matthieu SARABI          Sub-Investigator: Alice BONNEVILLE-LEVARD          Sub-Investigator: Nadège CORRADINI          Sub-Investigator: Louis DOUBLET          Sub-Investigator: Armelle DUFRESNE          Sub-Investigator: Lauriane EBERST          Sub-Investigator: Sylvie NEGRIER          Sub-Investigator: Katell MICHAUX          Sub-Investigator: Anne-Sophie MICHALLET          Sub-Investigator: Guillaume MAURICEAU          Sub-Investigator: Juliette REURE          Sub-Investigator: Pauline ROCHEFORT          Hopital Edouard Herriot Not yet recruiting Lyon, France, 69437 Contact: Julien FORESTIER, MD    +33472119738    julien.forestier@chu-lyon.fr    Principal Investigator: Julien FORESTIER          Sub-Investigator: Catherine LOMBARD BOHAS          Sub-Investigator: Thomas WALTER          Sub-Investigator: Yann MOLIN          Sub-Investigator: Noura BEN SLAMA          Institut Paoli Calmettes Recruiting Marseille, France, 13273 Contact: François BERTUCCI    +334 91 22 35 37    bertuccif@ipc.unicancer.fr    Principal Investigator: François BERTUCCI          Sub-Investigator: Jean-Marc EXTRA          Sub-Investigator: Anthony GONCALVES          Sub-Investigator: Gwenaêlle GRAVIS-MESCAM          Sub-Investigator: Anne MADROSZYK-FLANDIN          Sub-Investigator: Jean-Luc RAOUL          Sub-Investigator: Delphine PERROT          Sub-Investigator: Magali PROVENSAL          Sub-Investigator: Carole TARPIN          Sub-Investigator: Frédéric VIRET          Sub-Investigator: Louis TASSY          Sub-Investigator: Maria Antonietta CAPPIELLO          Sub-Investigator: Slimane DERMECHE          Sub-Investigator: Simon LAUNAY          Sub-Investigator: Frederique ROUSSEAU          Sub-Investigator: Nicolas MEYER          Sub-Investigator: Loïc MOUREY          Sub-Investigator: Elisabeth MOYAL          Sub-Investigator: Roxana Maria RADUT          Sub-Investigator: Henri ROCHE          Sub-Investigator: Thibaud VALENTIN          Sub-Investigator: Sarah ZAHI          Institut Curie Recruiting Paris, France, 75248 Contact: Christophe LE TOURNEAU, MD    +33144324672    Christophe.letourneau@curie.fr    Principal Investigator: Christophe LE TOURNEAU, MD          Sub-Investigator: Philippe BEUZEBOC          Sub-Investigator: François-Clément BIDARD          Sub-Investigator: Bruno BUECHER          Sub-Investigator: Paul-Henri COTTU          Sub-Investigator: Catherine DANIEL          Sub-Investigator: Véronique DIERAS          Sub-Investigator: Valérie LAURENCE          Sub-Investigator: Alain LIVARTOWSKI          Sub-Investigator: Jean-Yves PIERGA          Sub-Investigator: Marie ALT          Sub-Investigator: Delphine LOIRAT          Sub-Investigator: Marie-Paule SABLIN          Sub-Investigator: Mustapha ZOUBIR          Sub-Investigator: Francesco RICCI          Sub-Investigator: Emanuela ROMANO          Sub-Investigator: Olivier COLLARD          Centre Hospitalier Lyon Sud Recruiting Pierre-Bénite, France, 69495 Contact: Benoit YOU, MD    +33478864319    benoit.you@chu-lyon.fr    Principal Investigator: Benoit YOU, MD          Sub-Investigator: Nathalie BONNIN          Sub-Investigator: Gilles FREYER          Sub-Investigator: Salima HAMIZI          Sub-Investigator: Sophie TARTAS          Sub-Investigator: Véronique TRILLET-LENOIR          Sub-Investigator: Marion CHAUVENET          Sub-Investigator: Denis MAILLET          Sub-Investigator: Julien PERON          Sub-Investigator: Claire FALANDRY          Sub-Investigator: Olivia LE SAUX          Institut de cancérologie LUCIEN NEUWIRTH Not yet recruiting Saint-Priest-en-Jarez, France, 42270 Contact: Olivier COLLARD, MD    04 77 91 70 34    olivier.collard@icloire.fr    Principal Investigator: Olivier COLLARD, MD          Sub-Investigator: Claire BOSACKI, MD          Sub-Investigator: Pierre FOURNEL, MD          Sub-Investigator: Aline GUILLOT, MD          Sub-Investigator: Jean-Philippe JACQUIN, MD          Sub-Investigator: Thierry MURON, MD          Sub-Investigator: Léa SABAN-ROCHE, MD          Institut Claudius Regaud Recruiting Toulouse, France, 31059 Contact: Carlos-Alberto GOMEZ-ROCA    05 31 15 51 01    Gomez-roca.carlos@iuct-oncopole.fr    Principal Investigator: Carlos-Alberto GOMEZ-ROCA          Sub-Investigator: Christine CHEVREAU          Sub-Investigator: Ewa-Anna COTTURA          Sub-Investigator: Florence DALENC          Sub-Investigator: Jean-Pierre DELORD          Sub-Investigator: Marion DESLANDRES          Sub-Investigator: Cécile GANDY          Sub-Investigator: Laurence GLADIEFF          Sub-Investigator: Eleonora MAIO D'ESPOSITO          Sub-Investigator: Nicolas MEYER          Sub-Investigator: Loïc MOUREY          Sub-Investigator: Elisabeth MOYAL          Sub-Investigator: Henri ROCHE          Sub-Investigator: Thibaud VALENTIN          Sub-Investigator: Sarah ZAHI          Sub-Investigator: Roxana Maria RADUT Less <<
NCT02396108 Breast Cancer Phase 1 Phase 2 Recruiting March 2019 Singapore ... More >> National University Hospital Recruiting Singapore, Singapore, 119228 Contact: Soo Chin Lee    (65) 6779 5555 Less <<
NCT01479179 Breast Cancer Phase 1 Phase 2 Withdrawn(Drug sponsor decisio... More >>n to discontinue study.) Less << - -
NCT00795678 - Completed - United States, New York ... More >> Memorial Sloan Kettering New York, New York, United States, 10065 United States, Ohio Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Less <<
NCT02139358 - Active, not recruiting - -
NCT02559778 Neuroblastoma Phase 2 Recruiting September 2026 -
NCT00706030 - Completed - -
NCT00706030 Breast Cancer ... More >> Advanced Malignant Solid Tumors Less << Phase 1 Phase 2 Completed - -
NCT01306045 Carcinoma, Non-Small-Cell Lung... More >> Carcinoma, Small Cell Lung Carcinoma, Thymic Less << Phase 2 Recruiting December 30, 2019 United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    (888) NCI-1937 Less <<
NCT01058044 Cancer Not Applicable Completed - France ... More >> Centre Jean Perrin Clermont-Ferrand, France, 63011 Less <<
NCT03523585 Breast Cancer Phase 3 Recruiting February 2022 United States, California ... More >> Cancer Research Collaboration Recruiting Santa Ana, California, United States, 92705 Contact: Principal Investigator    562-981-6101    wademsmith@breastlink.com    United States, District of Columbia Washington Cancer Institute Recruiting Washington, District of Columbia, United States, 20010 Contact: Principal Investigator    202-877-9386    christopher.gallagher@medstar.net    United States, Georgia Piedmont Cancer Institute, PC Recruiting Atlanta, Georgia, United States, 30318 Contact: Principal Investigator    717-724-6780    rsinha@piedmontcancerinstitute.com    United States, New York North Shore Hematology Oncology Associates, PC Recruiting East Setauket, New York, United States, 11733 Contact: Principal Investigator    631-675-5111    researchpi@nycancer.com    United States, Ohio Dayton Physicians, LLC Recruiting Kettering, Ohio, United States, 45409 Contact: Principal Investigator    937-771-2422    cbane@precisioncancerresearch.com    United States, Utah Northern Utah Associates Recruiting Ogden, Utah, United States, 84405 Contact: Principal Investigator    801-387-7166    nua2@outlook.com    United States, Washington MultiCare Health System Institute for Research and Innovation Recruiting Tacoma, Washington, United States, 98405 Contact: Principal Investigator    253-403-3321    anu.belur@multicare.org    Japan NHO Shikoku Cancer Center Recruiting Ehime, Japan, 791-0280 Contact: See Central Contact          NHO Kyushu Cancer Center Recruiting Fukuoka, Japan, 811-1395 Contact: See Central Contact          Hiroshima City Hiroshima Citizens Hospital Recruiting Hiroshima, Japan, 730-8518 Contact: See Central Contact          NHO Hokkaido Cancer Center Recruiting Hokkaido, Japan, 003-0804 Contact: See Central Contact          Hyōgo College of Medicine Hospital Recruiting Hyōgo, Japan, 663-8501 Contact: See Central Contact          Kanagawa Cancer Center Recruiting Kanagawa, Japan, 241-8515 Contact: See Central Contact          Tohoku University Hospital Recruiting Miyagi, Japan, 980-8574 Contact: See Central Contact          Niigata Cancer Center Hospital Recruiting Niigata, Japan, 951-8566 Contact: See Central Contact          Okayama University Hospital Recruiting Okayama, Japan, 700-8558 Contact: See Central Contact          NHO Osaka National Hospital Recruiting Osaka, Japan, 540-0006 Contact: See Central Contact          Osaka International Cancer Institute Recruiting Osaka, Japan, 541-8567 Contact: See Central Contact          Saitama Cancer Center Recruiting Saitama, Japan, 362-0806 Contact: See Central Contact          The Cancer Institute Hospital of JFCR Recruiting Tokyo, Japan, 135-8550 Contact: See Central Contact          Tokyo Medical University Hospital Recruiting Tokyo, Japan, 160-0023 Contact: See Central Contact Less <<
NCT00495872 Solid Tumors Phase 1 Completed - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00897351 - Completed - -
NCT01441596 Breast Neoplasms ... More >> Neoplasm Metastasis Less << Phase 2 Completed - -
NCT01426880 Tubular Breast Cancer Stage II... More >> Mucinous Breast Cancer Stage II Breast Cancer Female NOS Invasive Ductal Breast Cancer Tubular Breast Cancer Stage III HER-2 Positive Breast Cancer Inflammatory Breast Cancer Stage IV Inflammatory Breast Cancer Less << Phase 2 Phase 3 Completed - Germany ... More >> Praxis Dr. Heinrich Fürstenwalde, Brandenburg, Germany, 15517 Luisenkrankenhaus Düsseldorf, Nordrhein-Westfalen, Germany, 40235 NCT Heidelberg Heidelberg, Germany Less <<
NCT01462604 - Completed - Hong Kong ... More >> GSK Investigational Site Pokfulam, Hong Kong GSK Investigational Site Shatin, Hong Kong Korea, Republic of GSK Investigational Site Seoul, Korea, Republic of, 120-752 Pakistan GSK Investigational Site Karachi, Pakistan GSK Investigational Site Lahore, Pakistan, 54600 Singapore GSK Investigational Site Singapore, Singapore, 258500 GSK Investigational Site Singapore, Singapore, 308433 Less <<
NCT01441596 - Completed - -
NCT01612351 Head and Neck Cancer ... More >> Squamous Cell Carcinoma of the Head and Neck Less << Phase 2 Active, not recruiting November 2031 United States, North Carolina ... More >> The University of North Carolina at Chapel Hill Chapel Hill, North Carolina, United States, 27599 Less <<
NCT00387205 Carcinoma, Renal Cell Phase 1 Completed - -
NCT01077648 - Completed - -
NCT03052634 Advanced Breast Cancer Phase 1 Phase 2 Recruiting December 2020 China, Beijing ... More >> Cancer Hospital Chinese Academy of Medical Sciences Recruiting Beijing, Beijing, China, 100021 Less <<
NCT01612351 - Active, not recruiting - -
NCT01891357 Carcinoma, Ductal, Breast Phase 2 Unknown December 2016 Germany ... More >> Klinikum Esslingen Recruiting Esslingen, Baden-Württemberg, Germany, 73730 Contact: Thorsten Kühn, MD    +49 711 3103 ext 3051       Contact: Angelika Jursik    +49 711 3103 ext 3064    angelikajursik@gmx.de    Principal Investigator: Thorsten Kühn, MD          SLK Kliniken Recruiting Heilbronn, Baden-Württemberg, Germany, 74078 Contact: Reinhard Hackenberg, MD    +49 7131 4934 ext 00       Principal Investigator: Reinhard Hackenberg, MD          Klinikum Frankfurt Höchst Recruiting Frankfurt (Main), Hessen, Germany, 65929 Contact: Volker Möbus, MD    +49 69 3106 ext 2339    volker.moebus@klinikumfrankfurt.de    Principal Investigator: Volker Möbus, MD          Niels-Stensen-Kliniken Recruiting Georgsmarienhütte, Niedersachsen, Germany, 49124 Contact: Albert von der Assen, MD    +49 541 502 ext 2275       Principal Investigator: Albert von der Assen, MD          Klinikum Westfalen GmbH - Knappschaftskrankenhaus Recruiting Dortmund, Nordrhein-Westfalen, Germany, 44309 Contact: Markus Skrobol, MD          Contact: Anna Moik    +49 231 9221 ext 078    studienzentrale@klinikum-westfalen.de    Principal Investigator: Markus Skrobol, MD          Bethesda Krankenhaus, Senologie Recruiting Duisburg, Nordrhein-Westfalen, Germany, 47053 Contact: Björn Wieland Lisboa, MD    +49 203 6008 ext 1270    senologie@bethesda.de    Principal Investigator: Björn Wieland Lisboa, MD          St. Barbara-KIinik Recruiting Hamm, Nordrhein-Westfalen, Germany, 59073 Contact: Herrmann Wiebringhaus, MD          Contact: Scharnewski Christiane    +49 2381 68123 ext 52    sscharnewski@barbaraklinik.de    Principal Investigator: Hermann Wiebringhaus, MD          Krankenhaus Köln Holweide, Brustzentrum Recruiting Köln, Nordrhein-Westfalen, Germany, 51067 Contact: Mathias Warm, MD    +49 221 8907 ext 6707    warmm@kliniken-koeln.de    Principal Investigator: Mathias Warm, MD          Klinikum Chemnitz gGmbH Recruiting Chemnitz, Sachsen, Germany, 09116 Contact: Nikos Fersis, MD    +49 371 333 ext 22200       Principal Investigator: Nikos Fersis, MD          Praxis für gynäkologische Onkologie am Brustzentrum City Recruiting Berlin, Germany, 10713 Contact: Lidia Perlova-Griff, MD          Contact: Michaela Platzer    +49 30 8272 ext 29840    michaela.platzer@sankt-gertrauden.de    Principal Investigator: Lidia Perlova-Griff, MD Less <<
NCT00295243 Advanced Solid Malignancies Phase 1 Completed - United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01304784 HER-2 Gene Amplification Phase 1 Completed - United States, Colorado ... More >> Rocky Mountain Cancer Centers Denver, Colorado, United States, 80218 United States, Georgia Georgia Cancer Specialists Atlanta, Georgia, United States, 30342 United States, Indiana Central Indiana Cancer Centers Indianapolis, Indiana, United States, 46151 Horizon Oncology Research, Inc Lafayette, Indiana, United States, 47908 United States, Nevada Comprehensive Cancer Centers of Nevada Las Vegas, Nevada, United States, 89135 United States, New York New York Oncology/Hematology Albany, New York, United States, 12206 United States, Ohio Innovation Center - Kettering Medical Center Health Network Kettering, Ohio, United States, 45429 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, South Carolina GHS Institute of Transitional Oncology Research Greenville, South Carolina, United States, 29605 United States, Texas Texas Oncology Cancer Center Austin, Texas, United States, 78731 Texas Oncology PA North/Sammans Cancer Center Dallas, Texas, United States, 75246 Texas Oncology - Tyler Tyler, Texas, United States, 75702 United States, Virginia Virginia Oncology Associates Norfolk, Virginia, United States, 23502 United States, Washington Evergreen Hematology and Oncology Spokane, Washington, United States, 99218 Northwest Cancer Specialists-Vancouver Cancer Center Vancouver, Washington, United States, 98684 Less <<
NCT01190241 Advanced Solid Tumors ... More >> Inoperable Metastasis Less << Not Applicable Unknown - Netherlands ... More >> Medical Center Alkmaar Alkmaar, Netherlands, 1815 JD VU University Medical Center Amsterdam, Netherlands, 1081 HV Less <<
NCT03500380 Breast Neoplasms ... More >> Breast Diseases Capecitabine HER2-positive Breast Cancer HER2 Positive Breast Carcinoma Less << Phase 2 Recruiting December 2020 China, Beijing ... More >> Cancer Hospital Chinese Academy of Medical Sciences Recruiting Beijing, Beijing, China, 100021 Contact: Binghe Xu          China, Liaoning The First Hospital of China Medical University Recruiting Shengyang, Liaoning, China Contact: Yuee teng          Liaoning Cancer Hospital & Institute Recruiting Shenyang, Liaoning, China Contact: Tao sun          China Peking Union Medical College Hospital Recruiting Beijing, China Contact: Qiang Sun          Peking University People's Hospital Recruiting Beijing, China Contact: Shu Wang          The First Hospital of Jilin University Recruiting Changchun, China Contact: Zhimin Fan          Hunan Cancer Hospital Recruiting Changsha, China Contact: Quchang Ouyang          Affiliated Hospital of Chengde Medical University Recruiting Chengde, China Contact: Qingshan Li          Sichuan Cancer Hospital Recruiting Chengdu, China Contact: Hui Li          West China Hospital Recruiting Chengdu, China Contact: Jing Jing          The Second Hospital of Dalian Medical University Recruiting Dalian, China Contact: Yang Zhang          Fujian Cancer Hospital Recruiting Fuzhou, China Contact: Jian Liu          Sun Yat-Sen Memorial Hospital Recruiting Guangzhou, China Contact: Herui Yao          The Affiliated Tumor Hospital of Guangzhou Medical University Recruiting Guangzhou, China Contact: Hongsheng Li          Guizhou Cancer Hospital Recruiting Guiyang, China Contact: Li Ran          The First Affiliated Hospital of Medical School of Zhejiang University Recruiting Hangzhou, China Contact: Peifen Fu          The Second Affiliated Hospital of Zhejiang University School of Medicine Recruiting Hangzhou, China Contact: Yongchuan Deng          Zhejiang Cancer Hospital Recruiting Hangzhou, China Contact: Xiaojia Wang          Harbin Medical University Cancer Hospital Recruiting Harbin, China Contact: Qingyuan Zhang          Anhui Cancer Hospital Recruiting Hefei, China Contact: Changlu Hu          Anhui Province Hospital Recruiting Hefei, China Contact: Yueyin Pan          The First Affiliated Hospital of Anhui Medical University Recruiting Hefei, China Contact: Kangsheng Gu          Qilu Hospital of Shandong University Recruiting Jinan, China Contact: Xiuwen Wang          Shandong Cancer Hospital Recruiting Jinan, China Contact: Yongsheng Wang          Linyi Cancer Hospital Recruiting Linyi, China Contact: Jingfen Wang          The First Affiliated Hospital of Henan University of Science & Technology Recruiting Luoyang, China Contact: Xinshuai Wang          Jiangxi Cancer Hospital Recruiting Nanchang, China Contact: Yudong Wu          Jiangsu Cancer Hospital Recruiting Nanjing, China Contact: Jifeng Feng          Jiangsu Province Hospital Recruiting Nanjing, China Contact: Yongmei Yin          The Affiliated Tumor Hospital of Guangxi Medical University Recruiting Nanning, China Contact: Weimin Xie          Yunnan Cancer Hospital Recruiting Nanning, China Contact: Dequan Liu          Hospital of Qingdao University Recruiting Qingdao, China Contact: Haibo Wang          Fudan University Shanghai Cancer Center Recruiting Shanghai, China Contact: Zhimin Shao          The Fourth Hospital of Hebei Medical University Recruiting Shijiazhuang, China Contact: Yunjiang Liu          Hubei Cancer Hospital Recruiting Wuhan, China Contact: Xinhong Wu          Wuhan Union Hospital Recruiting Wuhan, China Contact: Jing Cheng          The First Affiliated Hospital of the Fourth Military University of P.L.A. Recruiting Xi'an, China Contact: Yan Xue          The First Affiliated Hospital of Xi'an Jiaotong University Recruiting Xi'an, China Contact: Jin Yang          The Affiliated Hospital of Xuzhou Medical University Recruiting Xuzhou, China Contact: Zhengqiu Zhu          Xuzhou Central Hospital Recruiting Xuzhou, China Contact: Yong Liu          Yantai Yuhuangding Hospital Recruiting Yantai, China Contact: Liangming Zhang          Henan Cancer Hospital Recruiting Zhengzhou, China Contact: Min Yan          The First Affiliated Hospital of Zhengzhou University Recruiting Zhengzhou, China Contact: Yuanting Gu Less <<
NCT03418558 Metastatic Colorectal Cancer Phase 2 Recruiting June 2019 Italy ... More >> Fondazione del Piemonte per l'Oncologia Completed Candiolo, Italy, 10060 Grande Ospedale Metropolitano Niguarda Recruiting Milano, Italy Contact: Salvatore Siena, MD       salvatore.siena@ospedaleniguarda.it    IOV - Istituto Oncologico Veneto Completed Padova, Italy Less <<
NCT01104571 Breast Cancer Phase 3 Active, not recruiting September 2025 United Kingdom ... More >> Wythenshawe Hospital Manchester, England, United Kingdom, M23 9LJ Less <<
NCT01300962 Metastatic Breast Cancer Phase 1 Active, not recruiting December 2018 United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States, 27599 Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 Less <<
NCT02394496 Metastatic Breast Cancer Phase 3 Unknown January 2017 -
NCT00543504 Advanced Cancer Phase 1 Active, not recruiting October 2019 United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00436566 - Completed - -
NCT00709878 - Completed - -
NCT00436566 Breast Cancer ... More >> Cardiac Toxicity Less << Phase 2 Completed - United States, Minnesota ... More >> Mayo Clinic Cancer Research Consortium Rochester, Minnesota, United States, 55905 Less <<
NCT00709878 - Completed - United States, Illinois ... More >> Northwestern University Chicago, Illinois, United States, 60611 Less <<
NCT01248897 - Completed - Hong Kong ... More >> GSK Investigational Site Hong Kong, Hong Kong GSK Investigational Site Pokfulam, Hong Kong GSK Investigational Site Tuen Mun, Hong Kong GSK Investigational Site Wanchai, Hong Kong Korea, Republic of GSK Investigational Site Busan, Korea, Republic of, 602-030 GSK Investigational Site Busan, Korea, Republic of, 602-715 GSK Investigational Site Busan, Korea, Republic of, 602-739 GSK Investigational Site Gangwon-do, Korea, Republic of, 210-852 GSK Investigational Site Incheon, Korea, Republic of, 400-711 GSK Investigational Site Kyunggi-do, Korea, Republic of, 410-769 GSK Investigational Site Seoul, Korea, Republic of, 110-744 GSK Investigational Site Seoul, Korea, Republic of, 120-752 GSK Investigational Site Seoul, Korea, Republic of, 136-705 GSK Investigational Site Seoul, Korea, Republic of, 137-701 GSK Investigational Site Songpa-gu, Seoul, Korea, Republic of, 138-736 Philippines GSK Investigational Site Pasay City, Philippines, 1300 Singapore GSK Investigational Site Singapore, Singapore, 169610 Less <<
NCT00062686 Neoplasms, Breast PHASE2 COMPLETED 2025-02-05 GSK Investigational Site, Buen... More >>os Aires, C1455BWU, Argentina|GSK Investigational Site, Villejuif Cedex, 94805, France|GSK Investigational Site, Augsburg, Bayern, 86150, Germany|GSK Investigational Site, Sutton, Surrey, SM2 5PT, United Kingdom|GSK Investigational Site, Bebington, Wirral, CH63 4JY, United Kingdom|GSK Investigational Site, London, SW3 6JJ, United Kingdom|GSK Investigational Site, Manchester, M20 4BX, United Kingdom Less <<
NCT01462552 - Completed - -
NCT00567554 Breast Cancer Phase 3 Completed - Germany ... More >> Universitätsfrauenklinik Frankfurt / Main Frankfurt / Main, Germany Less <<
NCT01068704 Breast Cancer Phase 2 Completed - United States, Texas ... More >> Texas Oncology-Abilene Abilene, Texas, United States, 79606 Texas Oncology-Beaumont Beaumont, Texas, United States, 77702 Us Oncology Central Pharmacy Fort Worth, Texas, United States, 76177 United States, Washington Yakima Valley Memorial Hospital/North Star Lodge Yakima, Washington, United States, 98902 Argentina Local Institution Rosario, Santa Fe, Argentina, S2000DSK Local Institution La Rioja, Argentina, 5300 Mexico Local Institution Colima, Mexico, 28030 Peru Local Institution Lima, Peru, 34 Less <<
NCT00439179 Metastatic Pancreatic Cancer Phase 1 Completed - United States, Rhode Island ... More >> brown University oncology group Providence, Rhode Island, United States, 02912 Less <<
NCT00688194 Breast Cancer Phase 3 Unknown - Italy ... More >> Federico II University Medical School Recruiting Naples, Italy, 80131 Contact: Contact Person    39-081-746-3660 Less <<
NCT00482391 Breast Cancer Phase 2 Completed - United States, Massachusetts ... More >> Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Less <<
NCT00085020 Breast Cancer Phase 1 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095-1781 Less <<
NCT01526369 Metastatic Breast Cancer Phase 3 Active, not recruiting December 2018 -
NCT00898573 - Withdrawn - United States, Ohio ... More >> Geauga Regional Hospital Cleveland, Ohio, United States, 44024 Lake/University Ireland Cancer Center Cleveland, Ohio, United States, 44060 Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44106-5065 University Suburban Health Center Cleveland, Ohio, United States, 44121 UHHS Chagrin Highlands Medical Center Cleveland, Ohio, United States, 44122 Southwest General Health Center Cleveland, Ohio, United States, 44130 UHHS Westlake Medical Center Cleveland, Ohio, United States, 44145 Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States, 44195 Mercy Cancer Center at Mercy Medical Center Cleveland, Ohio, United States, 44708 Less <<
NCT00439179 - Completed - -
NCT00498953 Head and Neck Cancer Phase 1 Phase 2 Completed - Belgium ... More >> Institut Jules Bordet Brussels, Belgium, 1000 Less <<
NCT01172223 Breast Cancer Phase 1 Phase 2 Completed - Germany ... More >> Sana Klinikum Lichtenberg Berlin, Germany Less <<
NCT00482391 - Completed - -
NCT02056080 - Unknown October 2014 Spain ... More >> Recruiting Barcelona, Spain Recruiting Córdoba, Spain Recruiting Girona, Spain Recruiting Jaen, Spain Recruiting Madrid, Spain Recruiting Navarra, Spain Recruiting Salamanca, Spain Recruiting Santiago de Compostela, Spain Recruiting Sevilla, Spain Recruiting Valencia, Spain Recruiting Zaragoza, Spain Less <<
NCT00107003 Glioma Brain ... More >>Tumor Glioblastoma Multiforme GBM Gliosarcoma GS Less << Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00078572 Breast Cancer Phase 3 Completed - -
NCT00807859 Breast Cancer ... More >> Breast Neoplasms Breast Tumors Cancer Locally Recurrent and Metastatic Breast Cancer Metastases Metastatic Cancer Oncology Solid Tumors Tumors Less << Phase 1 Completed - United States, Arizona ... More >> Research Site Tucson, Arizona, United States, 85724 United States, Florida Research Site Boca Raton, Florida, United States, 33428 United States, Iowa Research Site Iowa City, Iowa, United States, 52242 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02111 United States, Minnesota Research Site Minneapolis, Minnesota, United States, 55407 United States, New Hampshire Research Site Lebanon, New Hampshire, United States, 03756-0001 Research Site Lebanon, New Hampshire, United States, 03756 United States, New Mexico Research Site Albuquerque, New Mexico, United States, 87131 United States, New York Research Site Great Neck, New York, United States, 11021 Research Site New City, New York, United States, 10956 Research Site New York, New York, United States, 10032 Research Site Nyack, New York, United States, 10960 United States, Ohio Research Site Middletown, Ohio, United States, 45042 Belgium Research Site Leuven, Belgium, 3000 Research Site Liege, Belgium, 4000 Research Site Wilrijk, Belgium, 2610 France Research Site Bordeaux, France, 33075 Research Site Caen Cedex 05, France, 14076 Research Site La Roche Sur Yon Cedex 9, France, 85925 Research Site Marseille, France, 13009 Research Site Nantes Cedex 2, France, 44202 Research Site Pierre Bénite Cedex, France, 69495 Research Site Toulouse, France, 31052 Less <<
NCT03273595 Neoplasms, Breast Phase 2 Recruiting December 2019 China, Shanxi ... More >> Xijing Hospital Recruiting Xi'an, Shanxi, China, 710032 Contact: Juliang Zhang, Doctor    +862984775271    zhangjl@fmmu.edu.cn    Principal Investigator: Juliang Zhang, Doctor Less <<
NCT00044343 Colorectal Cancer Phase 2 Completed - -
NCT00769470 Breast Cancer Phase 2 Completed - United States, California ... More >> Central Hematology Oncology Medical Group, Incorporated - Alhambra Alhambra, California, United States, 91801 Comprehensive Blood and Cancer Center Bakersfield, California, United States, 93309-0633 St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center Fullerton, California, United States, 92835 North Valley Hematology-Oncology Medical Group Northridge, California, United States, 91328 Wilshire Oncology Medical Group, Incorporated - Pomona Pomona, California, United States, 91767-3021 Sansum Medical Clinic Santa Barbara, California, United States, 93105 Central Coast Medical Oncology Corporation Santa Maria, California, United States, 93454 Santa Barbara Hematology Oncology - Solvang Solvang, California, United States, 93463 Cancer Care Associates Medical Group, Incorporated - Redondo Beach Torrance, California, United States, 90505 United States, Florida Cancer Institute of Florida, PA - Orlando Orlando, Florida, United States, 32804 Florida Hospital Cancer Institute Orlando, Florida, United States, 32804 Hematology and Oncology Consultants, PA - Orlando Orlando, Florida, United States, 32804 United States, Indiana Providence Medical Group Haute Terre, Indiana, United States, 47802 United States, Nevada Comprehensive Cancer Centers of Nevada - Henderson Henderson, Nevada, United States, 89052 United States, New Mexico New Mexico Cancer Center Albuquerque, New Mexico, United States, 87109 Less <<
NCT00450203 Oesophagogastric Cancer Phase 2 Phase 3 Unknown December 2017 United Kingdom ... More >> Royal Bournemouth Hospital Recruiting Bournemouth, England, United Kingdom, BH7 7DW Contact: Tom Geldart    44-1202-726-088       Bradford Royal Infirmary Active, not recruiting Bradford, England, United Kingdom, BD9 6RJ Bristol Haematology and Oncology Centre Recruiting Bristol, England, United Kingdom, BS2 8ED Contact: Stephen J. Falk, MD    44-117-928-3074    stephen.falk@ubht.nhs.uk    Addenbrooke's Hospital Active, not recruiting Cambridge, England, United Kingdom, CB2 2QQ Cumberland Infirmary Active, not recruiting Carlisle, England, United Kingdom, CA2 7HY Doncaster Royal Infirmary Recruiting Doncaster, England, United Kingdom, DN2 5LT Contact: Jonathan Wadsley    44-1302-366-666       St. Luke's Cancer Centre at Royal Surrey County Hospital Recruiting Guildford, England, United Kingdom, GU2 7XX Contact: Gary W. Middleton    44-1483-570-122    gmiddleton@royalsurrey.nhs.uk    Huddersfield Royal Infirmary Recruiting Huddersfield, West Yorks, England, United Kingdom, HD3 3EA Contact: Jo Dent    44-1484-342-000       Leeds Cancer Centre at St. James's University Hospital Recruiting Leeds, England, United Kingdom, LS9 7TF Contact: Matthew T. Seymour, MA, MD, FRCP    44-113-206-6400       Lincoln County Hospital Active, not recruiting Lincoln, England, United Kingdom, LN2 5QY Aintree University Hospital Recruiting Liverpool, England, United Kingdom, L9 7AL Contact: David Smith, MD    44-151-525-5980       Saint Bartholomew's Hospital Recruiting London, England, United Kingdom, EC1A 7BE Contact: Sarah Slater, MD    44-20-7601-8391       St. George's Hospital Active, not recruiting London, England, United Kingdom, SW17 0QT St. Mary's Hospital Active, not recruiting London, England, United Kingdom, W2 1NY Mid Kent Oncology Centre at Maidstone Hospital Recruiting Maidstone, England, United Kingdom, ME16 9QQ Contact: Justin Waters, MD    44-1622-729-000       Christie Hospital Recruiting Manchester, England, United Kingdom, M20 4BX Contact: Was Mansoor, MD    44-845-226-3000       Clatterbridge Centre for Oncology Recruiting Merseyside, England, United Kingdom, CH63 4JY Contact: David Smith, MD    44-151-334-1155    david.smith@ccotrust.nhs.uk    Northern Centre for Cancer Treatment at Newcastle General Hospital Recruiting Newcastle-Upon-Tyne, England, United Kingdom, NE4 6BE Contact: Fareeda Coxon, MD    44-191-256-3551    fareeda.coxon@nuth.nhs.uk    Derriford Hospital Active, not recruiting Plymouth, England, United Kingdom, PL6 8DH Dorset Cancer Centre Active, not recruiting Poole Dorset, England, United Kingdom, BH15 2JB Berkshire Cancer Centre at Royal Berkshire Hospital Recruiting Reading, England, United Kingdom, RG1 5AN Contact: Joss Adams, MD    44-118-322-7878       Rochdale Infirmary Active, not recruiting Rochdale, England, United Kingdom, 0L12 0NB Salisbury District Hospital Recruiting Salisbury, England, United Kingdom, SP2 8BJ Contact: Tim J. Iveson, MD    44-1722-336-262 ext. 4688       Wexham Park Hospital Recruiting Slough, Berkshire, England, United Kingdom, SL2 4HL Contact: Marcia Hall, MD    44-1753-634-364    marcia.hall@nhs.net.uk    Southampton General Hospital Recruiting Southampton, England, United Kingdom, SO16 6YD Contact: Tim J. Iveson, MD    44-23-8079-6802    t.iveson@soton.ac.uk    Royal Marsden - Surrey Recruiting Sutton, England, United Kingdom, SM2 5PT Contact: David Cunningham, MD    44-20-8661-3279    david.cunningham@rmh.nhs.uk    Aberdeen Royal Infirmary Recruiting Aberdeen, Scotland, United Kingdom, AB25 2ZN Contact: Russell Petty, MD    44-84-5456-6000       Velindre Cancer Center at Velindre Hospital Recruiting Cardiff, Wales, United Kingdom, CF14 2TL Contact: Tom Crosby, MD    44-29-2031-6292       Basingstoke and North Hampshire Hospital Recruiting Basingstoke, United Kingdom Principal Investigator: Charlotte Rees          Birmingham Heartlands Hospital Recruiting Birmingham, United Kingdom Principal Investigator: Jo Dent          Castle Hill Hospital Recruiting Cottingham, United Kingdom Principal Investigator: Mohan Hingorani          University Hospitals Coventry and Warwickshire Recruiting Coventry, United Kingdom Principal Investigator: Sharmila Sothi          Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom Principal Investigator: Janet Graham          St James Hospital Recruiting Leeds, United Kingdom Principal Investigator: Matt Seymour          Leicester Royal Infirmary Recruiting Leicester, United Kingdom Principal Investigator: Anne Thomas          Norfolk and Norwich University Hospital Recruiting Norwich, United Kingdom Principal Investigator: Tom Roques          Churchill Hospital Recruiting Oxford, United Kingdom Principal Investigator: Kinnari Patel          Queens Hospital Recruiting Romford, United Kingdom Principal Investigator: Sherif Raouf          Weston Park Recruiting Sheffield, United Kingdom Principal Investigator: Suzanne Darby          Great Western Hospital Recruiting Swindon, United Kingdom Principal Investigator: Claire Blesing          Musgrove Park Hospital Recruiting Taunton, United Kingdom Principal Investigator: Emma Cattell Less <<
NCT01471847 Locally Advance Breast Cancer ... More >>(LABC) Metastatic Breast Cancer (MBC) Less << Phase 1 Completed - Spain ... More >> Novartis Investigative Site Madrid, Spain, 28050 United Kingdom Novartis Investigative Site Leicester, United Kingdom, LE1 5WW Novartis Investigative Site Manchester, United Kingdom, M20 2BX Less <<
NCT00486668 Invasive Breast Cancer Phase 3 Unknown March 2017 -
NCT00281658 Neoplasms, Breast Phase 3 Active, not recruiting December 31, 2020 -
NCT01361945 Breast Cancer ... More >> Metastatic Breast Cancer HER-2 Positive Breast Cancer ER Positive Breast Cancer Less << Phase 1 Phase 2 Withdrawn(Closed due to no enr... More >>ollment) Less << - -
NCT02213042 Neoplasms, Breast Phase 2 Active, not recruiting March 4, 2019 -
NCT00281658 - Active, not recruiting - -
NCT00379509 Breast Cancer Phase 1 Completed - United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Less <<
NCT00437073 - Terminated(Lapatinib-topotecan... More >> arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.) Less << - -
NCT03084939 Breast Cancer Phase 3 Active, not recruiting October 5, 2019 China ... More >> Beijing Hospital Beijing City, China, 100006 The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA) Beijing, China, 100071 Beijing Cancer Hospital Beijing, China, 100142 Jilin Cancer Hospital Changchun, China, 130012 the First Hospital of Jilin University Changchun, China, 130021 Changzhou First People's Hospital Changzhou, China, 213003 West China Hospital, Sichuan University Chengdu, China, 610041 Fujian Medical University Union Hospital Fujian, China, 350001 Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department Hangzhou City, China, 310022 The Second Affiliated Hospital of Zhejiang University College Hangzhou, China, 310009 Harbin Medical University Cancer Hospital Harbin, China, 150081 Jiangsu Cancer Hospital Nanjing, China, 210009 Jiangsu Province Hospital Nanjing, China, 210036 Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China, 200025 Fudan University Shanghai Cancer Center Shanghai, China, 200032 Liaoning cancer Hospital & Institute Shenyang, China, 110042 Tianjin Cancer Hospital Tianjin, China, 300060 First Affiliated Hospital of Medical College of Xi'an Jiaotong University Xi'an, China, 710061 Less <<
NCT00388076 Neoplasms, Breast Phase 1 Completed - United States, New Jersey ... More >> GSK Investigational Site New Brunswick, New Jersey, United States, 08901 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44106 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Less <<
NCT00437073 Neoplasms, Breast Phase 2 Terminated(Lapatinib-topotecan... More >> arm enrollment closed early per protocol amendment 2. Then enrollment into remaining arm terminated due to operational issues.) Less << - -
NCT01973660 Breast Cancer Phase 2 Completed - Spain ... More >> Hospital de Torrevieja Torrevieja, Alicante, Spain Institut Català d'Oncologia Hospitalet Hospitalet de Llobregat, Barcelona, Spain Hospital Mutua de Terrassa Terrassa, Barcelona, Spain Consorcio Hospitalario Provincial de Castellón Castelló de la Plana, Castellón, Spain Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, Galicia, Spain Hospital Son Llàtzer Palma de Mallorca, Islas Baleares, Spain Hospital Universitario Son Espases Palma de Mallorca, Islas Baleares, Spain Hospital Universitario de Fuenlabrada Fuenlabrada, Madrid, Spain Hospital Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain Hospital Universitario Sant Joan de Reus Reus, Tarragona, Spain Hospital Luis Alcanyís de Xàtiva Xàtiva, Valencia, Spain, 46800 Hospital Universitario Infanta Cristina Badajoz, Spain, 06071 Vall d'Hebron University Hospital Barcelona, Spain, 08035 Hospital Clínic de Barcelona Barcelona, Spain Instituto Dexeus Barcelona, Spain Hospital San Pedro de Alcántara Cáceres, Spain, 10003 Hospital Universitario Arnau de Vilanova de Lleida Lleida, Spain Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Hospital Clínico San Carlos Madrid, Spain Hospital Universitario Ramón y Cajal Madrid, Spain Hospital Clínico Universitario de Valencia Valencia, Spain Hospital Universitario Arnau de Vilanova de Valencia Valencia, Spain Less <<
NCT00316407 Ovarian Epithelial Cancer Stag... More >>e III Stage IV Ovarian Cancer Stage IV Breast Cancer Less << Phase 1 Phase 2 Completed - United States, New Mexico ... More >> University of New Mexico Cancer Center Albuquerque, New Mexico, United States, 87131 United States, Washington Swedish Medical Center Cancer Institute Seattle, Washington, United States, 98104 Less <<
NCT00524303 Neoplasms, Breast Phase 2 Completed - United States, California ... More >> GSK Investigational Site Fountain Valley, California, United States, 92708 GSK Investigational Site Los Angeles, California, United States, 90057 United States, Colorado GSK Investigational Site Denver, Colorado, United States, 80220 United States, Florida GSK Investigational Site Hudson, Florida, United States, 34667 GSK Investigational Site Miami, Florida, United States, 33176 GSK Investigational Site Pembroke Pines, Florida, United States, 33028 United States, Indiana GSK Investigational Site Indianapolis, Indiana, United States, 46219 United States, Nevada GSK Investigational Site Henderson, Nevada, United States, 89052 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19107 United States, Texas GSK Investigational Site Austin, Texas, United States, 78731 GSK Investigational Site Beaumont, Texas, United States, 77702-1449 GSK Investigational Site Bedford, Texas, United States, 76022 GSK Investigational Site Dallas, Texas, United States, 75231 GSK Investigational Site Dallas, Texas, United States, 75246 GSK Investigational Site Dallas, Texas, United States, 75320-2510 GSK Investigational Site El Paso, Texas, United States, 79915 GSK Investigational Site Houston, Texas, United States, 77024 GSK Investigational Site Lewisville, Texas, United States, 75067 GSK Investigational Site Sugar Land, Texas, United States, 77479 GSK Investigational Site Tyler, Texas, United States, 75702 United States, Virginia GSK Investigational Site Norfolk, Virginia, United States, 23502 United States, Washington GSK Investigational Site Seattle, Washington, United States, 98117 GSK Investigational Site Yakima, Washington, United States, 98902 Less <<
NCT00075270 Neoplasms, Breast Phase 3 Completed - -
NCT00404066 Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 2 Completed - United States, California ... More >> Santa Clara Valley Medical Center San Jose, California, United States, 95128 Stanford University School of Medicine Stanford, California, United States, 94305 Less <<
NCT00404066 - Completed - -
NCT00075270 - Completed - -
NCT00450892 Breast Cancer Phase 1 Phase 2 Completed - Belgium ... More >> C.H.U. Sart-Tilman Liege, Belgium Clinique Sainte Elisabeth Namur, Belgium France Institut Bergonie Bordeaux, France Institut Bergonié Bordeaux, France CHRU de Limoges Limoges, France Centre Leon Berard Lyon, France CRLC Val D'Aurelle Montpellier, France Centre Henri Becquerel Rouen, France Hopital Rene Huguenin - Institut Curie Saint-Cloud, France Centre Paul Strauss Strasbourg, France Institut Gustave Roussy Villejuif, France Slovenia The Institute Of Oncology Ljubljana, Slovenia Switzerland Hôpitaux universitaires de Genève - HUG - site de Cluse-Roseraie Geneve, Switzerland Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland United Kingdom Western General Hospital Edinburgh, United Kingdom Less <<
NCT00524303 - Completed - -
NCT00770809 - Active, not recruiting - -
NCT00770809 HER2/Neu Positive ... More >> Male Breast Carcinoma Stage IIA Breast Cancer AJCC v6 and v7 Stage IIB Breast Cancer AJCC v6 and v7 Stage IIIA Breast Cancer AJCC v7 Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Less << Phase 3 Active, not recruiting - -
NCT00756470 Breast Cancer Phase 2 Terminated(Slow accrual.) - United States, Texas ... More >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00756470 - Terminated(Slow accrual.) - -
NCT00667251 Breast Cancer Phase 3 Active, not recruiting December 31, 2020 -
NCT00148902 Neoplasms, Breast Phase 1 Completed - United States, Michigan ... More >> GSK Investigational Site Detroit, Michigan, United States, 48201 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 Less <<
NCT01123473 Adenocarcinoma of the Gastroes... More >>ophageal Junction Gastric Cancer Less << Phase 2 Terminated(company withdrew in... More >>terest) Less << - Belgium ... More >> Institut Jules Bordet Brussels, Belgium U.Z. Gasthuisberg Leuven, Belgium Germany Johannes Gutenberg Universitaetskliniken Mainz, Germany Portugal I.P.O. Francisco Gentil - Centro De Lisboa Lisboa, Portugal Less <<
NCT00347919 Neoplasms, Breast Phase 2 Completed - -
NCT01205217 Neoplasms, Breast Phase 2 Withdrawn(Data presented at SA... More >>BCS 2010 showing that dual blockade is superior to monotherapy) Less << December 2010 Austria ... More >> GSK Investigational Site Graz, Austria, A-8036 Hungary GSK Investigational Site Budapest, Hungary, 1122 GSK Investigational Site Gyula, Hungary, 5700 Norway GSK Investigational Site Oslo, Norway, 0310 GSK Investigational Site Oslo, Norway, 0407 Spain GSK Investigational Site Castellón, Spain, 12002 Less <<
NCT00347919 - Completed - -
NCT01711658 Non-HPV Locally Advanced Head ... More >>and Neck Cancer Less << Phase 2 Active, not recruiting March 31, 2023 United States, Alabama ... More >> University of Alabama at Birmingham Comprehensive Cancer Center Birmingham, Alabama, United States, 35294 United States, California University of California, San Diego La Jolla, California, United States, 92093 Sutter General Hospital Sacramento, California, United States, 95816 University of California San Francisco San Francisco, California, United States, 94143 United States, Connecticut Yale University New Haven, Connecticut, United States, 06520 United States, Georgia Emory University Atlanta, Georgia, United States, 30308 United States, Kentucky James Graham Brown Cancer Center at University of Louisville Louisville, Kentucky, United States, 40202 United States, Ohio University Hospitals of Cleveland Cleveland, Ohio, United States, 44106 Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, Oklahoma University of Oklahoma Health Sciences Center Oklahoma City, Oklahoma, United States, 73190 United States, Pennsylvania Fox Chase Cancer Center Buckingham Furlong, Pennsylvania, United States, 18925 United States, Texas University of Texas Southwestern Medical School Dallas, Texas, United States, 75390 University of Texas - MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 United States, Wisconsin University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 Medical College of Wisconsin Milwaukee, Wisconsin, United States, 53226 Canada, Quebec McGill Cancer Centre at McGill University Montreal, Quebec, Canada, H2W 1S6 Less <<
NCT00667251 - Active, not recruiting - -
NCT00338247 - - - -
NCT01382706 Recurrent Bladder Cancer ... More >> Stage III Bladder Cancer Stage IV Bladder Cancer Transitional Cell Carcinoma of the Bladder Less << Phase 2 Terminated(Trial not progressi... More >>ng toward scientific goals) Less << - United States, California ... More >> USC/Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Less <<
NCT00422903 Neoplasms, Breast Phase 2 Completed - Italy ... More >> GSK Investigational Site Carpi (MO), Emilia-Romagna, Italy, 41012 GSK Investigational Site Forlì, Emilia-Romagna, Italy, 47100 GSK Investigational Site Modena, Emilia-Romagna, Italy, 41100 GSK Investigational Site Piacenza, Emilia-Romagna, Italy, 29100 GSK Investigational Site Rimini, Emilia-Romagna, Italy, 47900 GSK Investigational Site Treviglio (BG), Lombardia, Italy, 24047 GSK Investigational Site Brindisi, Puglia, Italy, 72100 GSK Investigational Site Pisa, Toscana, Italy, 56126 GSK Investigational Site Chieti, Italy, 66100 GSK Investigational Site Cremona, Italy, 26100 GSK Investigational Site Perugia, Italy, 06156 GSK Investigational Site Reggio Emilia, Italy, 42100 GSK Investigational Site Varese, Italy, 21100 Spain GSK Investigational Site Badalona, Spain, 08916 Less <<
NCT00089999 Neoplasms, Breast PHASE2 COMPLETED 2025-03-08 GSK Investigational Site, Holl... More >>ywood, Florida, 33021, United States|GSK Investigational Site, Santiago, Región Metro De Santiago, 7500921, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, 8380456, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Delhi, 110085, India|GSK Investigational Site, Hyderabad, Andhra Pradesh, 500482, India|GSK Investigational Site, Pune, 411001, India|GSK Investigational Site, Bandar Tun Razak, Cheras, 59100, Malaysia|GSK Investigational Site, Kubang Kerian, 16150, Malaysia|GSK Investigational Site, Tanjong Bungah, 10450, Malaysia|GSK Investigational Site, Tanjong Bungah, 11200, Malaysia|GSK Investigational Site, Ixtaltepec / Espinal, Oaxaca, 70140, Mexico|GSK Investigational Site, Merida, Yucatán, 97500, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Karachi, 54000, Pakistan|GSK Investigational Site, Karachi, 74800, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Rawalpindi, Pakistan|GSK Investigational Site, Callao, Callao 2, Peru|GSK Investigational Site, Lima, Lima 11, Peru|GSK Investigational Site, Lima, Lima 13, Peru|GSK Investigational Site, Lima, Lima 34, Peru|GSK Investigational Site, Bydogoszcz, 85-796, Poland|GSK Investigational Site, Krakow, 31-115, Poland|GSK Investigational Site, Olsztyn, 10-228, Poland|GSK Investigational Site, Singapore, 169610, Singapore|GSK Investigational Site, Singapore, 258500, Singapore|GSK Investigational Site, Taipei, 100, Taiwan|GSK Investigational Site, Taipei, 114, Taiwan Less <<
NCT00073008 - Terminated(Based on interim an... More >>alysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy) Less << - -
NCT00073008 Lung Cancer, Non-Small Cell Phase 2 Terminated(Based on interim an... More >>alysis at the end of Stage 1, and predefined stopping rules for futility, further enrollment was stopped due to lack of efficacy) Less << - -
NCT00662636 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00422903 - Completed - -
NCT00455039 Breast Cancer PHASE1|PHASE2 WITHDRAWN 2023-07-31 UNM CRTC, Albuquerque, New Mex... More >>ico, 87106, United States Less <<
NCT00251433 Neoplasms, Breast Phase 1 Active, not recruiting December 31, 2019 United States, Tennessee ... More >> Novartis Investigative Site Nashville, Tennessee, United States, 37203 France Novartis Investigative Site Paris Cedex 10, France, 75475 Novartis Investigative Site Paris Cedex 5, France, 75248 Ireland Novartis Investigative Site Dublin, Ireland, 4 Novartis Investigative Site Dublin, Ireland, 8 Less <<
NCT00389922 Unspecified Adult Solid Tumor,... More >> Protocol Specific Less << Phase 1 Completed - United States, California ... More >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010-3000 USC/Norris Comprehensive Cancer Center and Hospital Los Angeles, California, United States, 90089-9181 University of California Davis Cancer Center Sacramento, California, United States, 95817 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109-1023 Less <<
NCT00099060 Brain and Central Nervous Syst... More >>em Tumors Less << Phase 1 Phase 2 Completed - Canada, Alberta ... More >> Tom Baker Cancer Centre - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 British Columbia Cancer Agency - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 Less <<
NCT00841828 - Completed - -
NCT00272987 Neoplasms, Breast Phase 3 Active, not recruiting December 31, 2018 -
NCT00089999 Neoplasms, Breast PHASE2 COMPLETED 2025-03-08 GSK Investigational Site, Holl... More >>ywood, Florida, 33021, United States|GSK Investigational Site, Santiago, Región Metro De Santiago, 7500921, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, 8380456, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Delhi, 110085, India|GSK Investigational Site, Hyderabad, Andhra Pradesh, 500482, India|GSK Investigational Site, Pune, 411001, India|GSK Investigational Site, Bandar Tun Razak, Cheras, 59100, Malaysia|GSK Investigational Site, Kubang Kerian, 16150, Malaysia|GSK Investigational Site, Tanjong Bungah, 10450, Malaysia|GSK Investigational Site, Tanjong Bungah, 11200, Malaysia|GSK Investigational Site, Ixtaltepec / Espinal, Oaxaca, 70140, Mexico|GSK Investigational Site, Merida, Yucatán, 97500, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Karachi, 54000, Pakistan|GSK Investigational Site, Karachi, 74800, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Rawalpindi, Pakistan|GSK Investigational Site, Callao, Callao 2, Peru|GSK Investigational Site, Lima, Lima 11, Peru|GSK Investigational Site, Lima, Lima 13, Peru|GSK Investigational Site, Lima, Lima 34, Peru|GSK Investigational Site, Bydogoszcz, 85-796, Poland|GSK Investigational Site, Krakow, 31-115, Poland|GSK Investigational Site, Olsztyn, 10-228, Poland|GSK Investigational Site, Singapore, 169610, Singapore|GSK Investigational Site, Singapore, 258500, Singapore|GSK Investigational Site, Taipei, 100, Taiwan|GSK Investigational Site, Taipei, 114, Taiwan Less <<
NCT00820872 Breast Cancer Phase 2 Active, not recruiting - -
NCT00316875 Breast Cancer Phase 1 Completed - United States, Illinois ... More >> Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago, Illinois, United States, 60611-3013 Less <<
NCT00272987 - Active, not recruiting - -
NCT00390455 Estrogen Receptor Positive ... More >> HER2 Positive Breast Carcinoma HER2/Neu Negative Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IIIB Breast Cancer AJCC v7 Stage IIIC Breast Cancer AJCC v7 Stage IV Breast Cancer AJCC v6 and v7 Less << Phase 3 Active, not recruiting - -
NCT00103324 Diffuse Adenocarcinoma of the ... More >>Stomach Intestinal Adenocarcinoma of the Stomach Mixed Adenocarcinoma of the Stomach Recurrent Gastric Cancer Stage III Gastric Cancer Stage IV Gastric Cancer Less << Phase 2 Completed - United States, Texas ... More >> Southwest Oncology Group San Antonio, Texas, United States, 78245 Less <<
NCT00820872 - Active, not recruiting - -
NCT00841828 Breast Cancer Phase 2 Phase 3 Completed - Spain ... More >> Hospital Central de Asturias Oviedo, Asturias, Spain, 33006 Hospital Germans Trias i Pujol Badalona, Barcelona, Spain, 08916 Hospital General de Granollers Granollers, Barcelona, Spain, 08400 Xarxa Asistencial de Manresa Manresa, Barcelona, Spain, 08243 Corporación Sanitaria Parc Taulí Sabadell, Barcelona, Spain, 08208 Hospital del Espíritu Santo Santa Coloma De Gramenet, Barcelona, Spain, 08923 Consorci Sanitari de Terrassa Terrassa, Barcelona, Spain, 08221 Hospital Mutua de Terrassa Terrassa, Barcelona, Spain, 08221 Onkologikoa Donostia-San Sebastián, Guipuzcoa, Spain, 20012 Hospital Xeral Cíes Vigo, Pontevedra, Spain, 36204 Hospital Universitario de Canarias La Laguna, Santa Cruz De Tenerife, Spain, 38320 Complejo Hospitalario Universitario A Coruña A Coruña, Spain, 15006 Centro Oncológico de Galicia A Coruña, Spain, 15009 Hospital del Mar Barcelona, Spain, 08003 Hospital Clinic i Provincial Barcelona, Spain, 08036 Hospital de la Santa Creu i Sant Pau Barcelona, Spain, 08041 Hospital General Yagüe Burgos, Spain, 09005 Complejo Hospitalario San Pedro de Alcántara Cáceres, Spain, 10003 Complejo Hospitalario Universitario Reina Sofía Córdoba, Spain, 14004 Complejo Hospitalario de Jaén Jaén, Spain, 23007 Hospital Universitario de la Princesa Madrid, Spain, 28006 Hospital Clínico Universitario Virgen de la Victoria Málaga, Spain, 29010 Hospital Virgen de la Salud Toledo, Spain, 45004 Hospital Universitario La Fe Valencia, Spain, 46009 Hospital Clinico Universitario de Valencia Valencia, Spain, 46010 Hospital Universitario Miguel Servet Zaragoza, Spain, 50009 Less <<
NCT01137994 Neoplasms, Breast Phase 2 Withdrawn March 2018 -
NCT00429299 Neoplasms, Breast Phase 2 Completed - Germany ... More >> GSK Investigational Site Berlin, Germany, 13125 Italy GSK Investigational Site Carpi (MO), Emilia-Romagna, Italy, 41012 GSK Investigational Site Forlì, Emilia-Romagna, Italy, 47100 GSK Investigational Site Modena, Emilia-Romagna, Italy, 41100 GSK Investigational Site Parma, Emilia-Romagna, Italy, 43100 GSK Investigational Site Piacenza, Emilia-Romagna, Italy, 29100 GSK Investigational Site Rimini, Emilia-Romagna, Italy, 47900 GSK Investigational Site Treviglio (BG), Lombardia, Italy, 24047 GSK Investigational Site Candiolo (TO), Piemonte, Italy, 10060 GSK Investigational Site Brindisi, Puglia, Italy, 72100 GSK Investigational Site Pisa, Toscana, Italy, 56126 GSK Investigational Site Cremona, Italy, 26100 GSK Investigational Site Pavia, Italy, 27100 GSK Investigational Site Perugia, Italy, 06156 GSK Investigational Site Reggio Emilia, Italy, 42100 GSK Investigational Site Varese, Italy, 21100 Poland GSK Investigational Site Warszawa, Poland, 00-909 Less <<
NCT00390455 - Active, not recruiting - -
NCT00429299 - Completed - -
NCT01005641 Breast Cancer Phase 2 Withdrawn(Study not started fo... More >>r administrative reasons) Less << March 2012 Italy ... More >> Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B Napoli, Italy, 80131 Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C Napoli, Italy, 80131 Ospedale S. Luca ASL SA 3 Vallo della Lucania, Italy Less <<
NCT01160094 - Completed - Colombia ... More >> Novartis Investigative Site Bogota, Colombia Novartis Investigative Site Bogotá, Colombia Novartis Investigative Site Bucaramanga, Colombia Novartis Investigative Site Medellin, Colombia Novartis Investigative Site Pasto, Colombia Novartis Investigative Site Pereira, Colombia Saudi Arabia Novartis Investigative Site Dammam, Saudi Arabia, Dammam 31444 Novartis Investigative Site Jeddah, Saudi Arabia, 21499 Novartis Investigative Site Jeddah, Saudi Arabia, jEDDAH 21423 Novartis Investigative Site Jeddah, Saudi Arabia Novartis Investigative Site Riyadh, Saudi Arabia Less <<
NCT00073528 Neoplasms, Breast Phase 3 Completed - -
NCT00513253 Healthy Subjects Phase 1 Withdrawn(It was determined no... More >>t to be needed based on the clinical development plan of Tykerb.) Less << May 2008 United States, New York ... More >> GSK Investigational Site Buffalo, New York, United States, 14202 Less <<
NCT01161368 Metastatic Breast Cancer Phase 2 Terminated(poor recruitment) - Austria ... More >> Dep. of Medicine I , Division of Oncology Vienna, Austria, 1090 Hungary National Institute of Oncology Budapest, Hungary Less <<
NCT00632489 Breast Cancer Phase 1 Completed - United States, Tennessee ... More >> Tennessee Oncology, PLLC Nashville, Tennessee, United States, 37023 Less <<
NCT01138046 Neoplasms, Breast Phase 2 Completed - Japan ... More >> GSK Investigational Site Aichi, Japan, 464-8681 GSK Investigational Site Ehime, Japan, 791-0280 GSK Investigational Site Hyogo, Japan, 673-8558 GSK Investigational Site Kagoshima, Japan, 892-0833 GSK Investigational Site Kanagawa, Japan, 241-8515 GSK Investigational Site Osaka, Japan, 540-0006 GSK Investigational Site Osaka, Japan, 565-0871 GSK Investigational Site Saitama, Japan, 350-1298 GSK Investigational Site Saitama, Japan, 362-0806 GSK Investigational Site Tokyo, Japan, 113-8677 Less <<
NCT00632489 - Completed - -
NCT00826241 Brain Tumors ... More >>Spinal Cord Tumors Less << Phase 2 Completed - United States, California ... More >> University of California, San Francisco San Francisco, California, United States, 94143 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Pennsylvania University of Pittsburgh Medical Center - Hillman Cancer Center Pittsburgh, Pennsylvania, United States, 15232 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin School of Medicine and Public Health Madison, Wisconsin, United States, 53792 Less <<
NCT00073528 - Completed - -
NCT02551718 Acute Leukemia of Ambiguous Li... More >>neage Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Lymphoblastic Leukemia Recurrent Childhood Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia Refractory Adult Acute Lymphoblastic Leukemia Refractory Childhood Acute Lymphoblastic Leukemia Less << Not Applicable Recruiting - United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Pamela S. Becker    206-616-1589    pbecker@u.washington.edu    Principal Investigator: Pamela S. Becker Less <<
NCT01534455 Metastatic Breast Cancer Phase 2 Terminated(very slow patient r... More >>ecruitment and concerns about the actuality of the study design) Less << - Germany ... More >> Klinikum der Otto-v.-Guericke-Universität Frauenklinik Magdeburg, Germany, 39108 Less <<
NCT02142036 Metastatic Cancer Phase 2 Active, not recruiting January 2022 Norway ... More >> Akershus University Hospital Lillestrøm, Norway, 1478 The Norwegian Radium Hospital Oslo, Norway, 0379 Less <<
NCT01494662 Breast Cancer Phase 2 Recruiting December 2023 United States, California ... More >> University of California, San Francisco Medical Center Active, not recruiting San Francisco, California, United States, 94115 United States, District of Columbia MedStar Georgetown Univeristy Hospital Active, not recruiting Washington, District of Columbia, United States, 20007 United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Active, not recruiting Baltimore, Maryland, United States, 21231 United States, Massachusetts Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Rachel Freedman, MD          Principal Investigator: Rachel Freedman, MD, MPH          Massachusetts General Hosptial Recruiting Boston, Massachusetts, United States, 02215 Contact: Beverly Moy, MD          Principal Investigator: Beverly Moy, MD          United States, Michigan University of Michigan Comprehensive Cancer Center Active, not recruiting Ann Arbor, Michigan, United States, 48109 United States, North Carolina University of North Carolina at Chapel Hill - Lineberger Comprehensive Cancer Center Active, not recruiting Chapel Hill, North Carolina, United States, 27599 Duke University Medical Center Active, not recruiting Durham, North Carolina, United States, 27710 United States, Pennsylvania UPMC Cancer Centers - Magee-Womens Hospital of UPMC Active, not recruiting Pittsburgh, Pennsylvania, United States, 15213 United States, Texas Baylor College of Medicine Lester and Sue Smith Breast Center Active, not recruiting Houston, Texas, United States, 77030 MD Anderson Cancer Center Active, not recruiting Houston, Texas, United States, 77030 Less <<
NCT03262935 Metastatic Breast Cancer Phase 3 Recruiting May 2021 -
NCT02645149 Melanoma Phase 4 Not yet recruiting August 2021 Australia, New South Wales ... More >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez    612 9911 7200    maria.gonzalez@melanoma.org.au    Principal Investigator: John Thompson          Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez    +612 9911 7200    maria.gonzalez@melanoma.org.au    Contact: Alex Menzies    +612 9911 7200    info@melanoma.org.au    Sub-Investigator: Georgina Long          Principal Investigator: Alex Menzies Less <<
NCT01138046 - Completed - -
NCT02208583 Hormone Refractory Prostate Ca... More >>ncer Less << Not Applicable Unknown December 2016 China, Tianjin ... More >> Department of Interventional Oncology, Tianjin Medical University Cancer Institute and Hospital Recruiting Tianjin, Tianjin, China, 300060 Contact: Wang HaiTao, Ph.D    +86-18630955984    peterrock2000@126.com    Principal Investigator: Wang HaiTao, Ph.D Less <<
NCT02836847 Cholangiocarcinoma of the Extr... More >>ahepatic Bile Duct Gallbladder Cancer Less << Phase 2 Recruiting December 2020 China, Shanghai ... More >> Xinhua Hospital Recruiting Shanghai, Shanghai, China, 200092 Contact: yingbin liu    13918803900    laoniulyb@163.com Less <<
NCT01636908 Cancer Advanc... More >>ed Solid Tumors Less << Not Applicable Active, not recruiting - Netherlands ... More >> VUMedical Center Amsterdam, Netherlands, 1081 HV Less <<
NCT02788201 Urothelial Carcinoma ... More >> Bladder Cancer Urinary Bladder Neoplasms Less << Phase 2 Recruiting July 1, 2020 United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office    888-624-1937 Less <<
NCT03768375 Cholangiocarcinoma of the Extr... More >>ahepatic Bile Duct Gallbladder Cancer Less << Phase 2 Recruiting December 30, 2021 China, Shanghai ... More >> Xinhua Hospital Recruiting Shanghai, Shanghai, China, 200092 Contact: Yingbin Liu, PHD    13918803900    laoniulyb@163.com    Principal Investigator: yingbin liu, PHD Less <<
NCT01419197 - Completed - -
NCT01098500 - Completed - -
NCT00363194 Carcinoma, Renal Cell Phase 1 Completed - United States, Indiana ... More >> GSK Investigational Site Indianapolis, Indiana, United States, 46202 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 Less <<
NCT01152853 Advanced Gastric Cancer ... More >> HER2 Less << Phase 2 Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Korea, Republic of, 110-744 Less <<
NCT01098500 - Completed - -
NCT01466504 - Terminated(Accrual did not mee... More >>t expectations. Over nearly 2 years just 4 subjects were treated on study. The goal of 30 subjects was not attainable.) Less << - United States, New Hampshire ... More >> Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center Lebanon, New Hampshire, United States, 03756 United States, Vermont White River Junction VA Medical Center White River Junction, Vermont, United States, 05009 Less <<
NCT03755141 HER2-positive Breast Cancer ... More >> Metastatic Breast Cancer Less << Phase 2 Not yet recruiting June 30, 2022 -
NCT01064349 - Completed - Philippines ... More >> GSK Investigational Site Pasay City, Philippines, 1300 GSK Investigational Site Quezon City, Philippines, 1101 GSK Investigational Site Quezon City, Philippines, 1102 Singapore GSK Investigational Site Singapore, Singapore, 119074 Thailand GSK Investigational Site Bangkok, Thailand, 10110 GSK Investigational Site Bangkok, Thailand, 10310 GSK Investigational Site Bangkok, Thailand, 10330 GSK Investigational Site Bangkok, Thailand, 10400 GSK Investigational Site Bangkok, Thailand, 10700 GSK Investigational Site Chiangmai, Thailand, 50200 Less <<
NCT01565200 HER-2 Positive Breast Cancer Phase 2 Active, not recruiting December 2019 Belgium ... More >> Universitair Ziekenhuis Antwerpen (UZA) Antwerpen, Edegem, Belgium, 2650 Institut Jules Bordet Brussels, Belgium, 1000 Netherlands Vrije Universiteit Amsterdam (VUMC) Amsterdam, Netherlands, 1081HV University Medical Center Groningen (UMCG) Groningen, Netherlands, 9700RB Radboud University Medical Centre Nijmegen (UMCN) Nijmegen, Netherlands, 6525 GA Less <<
NCT01419197 Breast Cancer Phase 3 Completed - -
NCT00883688 Brain Cancer ... More >>Pediatric Cancers Less << Phase 2 Completed - United States, California ... More >> Stanford University Medical Center Stanford, California, United States, 94305 United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614 United States, Ohio Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee St. Jude Children's Research Hospital Memphis, Tennessee, United States, 38105 United States, Texas University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01454804 Advanced Cancers Phase 1 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01594177 Unilateral HER2 Positive Breas... More >>t Cancer Less << Phase 2 Completed - Germany ... More >> Rotkreuzklinikum München München, Germany, 80634 Less <<
NCT01705340 Adenocarcinoma of the Gastroes... More >>ophageal Junction HER2-positive Breast Cancer Male Breast Cancer Recurrent Breast Cancer Recurrent Esophageal Cancer Recurrent Gastric Cancer Stage IIIC Breast Cancer Stage IIIC Esophageal Cancer Stage IIIC Gastric Cancer Stage IV Breast Cancer Stage IV Esophageal Cancer Stage IV Gastric Cancer Less << Phase 1 Terminated - United States, New York ... More >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01431196 Stage II Breast Cancer ... More >> Stage III Breast Cancer Less << Phase 2 Completed - Spain ... More >> Clínica Universidad de Navarra Pamplona, Navarra, Spain, 31008 Less <<
NCT00508274 - Active, not recruiting - -
NCT00508274 Neoplasms, Breast Phase 3 Active, not recruiting April 10, 2020 China, Guangdong ... More >> Novartis Investigative Site Guangzhou, Guangdong, China, 510060 Novartis Investigative Site Guangzhou, Guangdong, China, 510515 China, Hubei Novartis Investigative Site Wuhan, Hubei, China, 430030 China, Jiangsu Novartis Investigative Site Nanjing, Jiangsu, China, 210009 China, Zhejiang Novartis Investigative Site Hangzhou, Zhejiang, China, 310006 Novartis Investigative Site Hangzhou, Zhejiang, China, 310022 China Novartis Investigative Site Beijing, China, 100021 Novartis Investigative Site Beijing, China, 100071 Novartis Investigative Site Shanghai, China, 200032 Hong Kong Novartis Investigative Site Hong Kong, Hong Kong Novartis Investigative Site Shatin, Hong Kong Less <<
NCT01771458 Reccurent/Metastatic Solid Tum... More >>or Disease Less << Phase 2 Unknown December 2016 France ... More >> Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc Dijon, France, 21079 Centre Leon Berard Lyon, France, 69373 Institut Paoli Calmettes Marseille, France, 13009 Insitut Curie Paris, France, 75248 Institut Curie Hopital Rene Huguenin Saint-cloud, France, 92210 Institut de cancérologie de l'Ouest Centre René Gauducheau Saint-herblain, France, 44000 Institut Claudius Régaud Toulouse, France, 31052 Centre Alexis Vautrin Vandoeuvre Les Nancy, France, 54500 Less <<
NCT01245205 HER2-positive Breast Cancer ... More >> Male Breast Cancer Recurrent Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Unspecified Adult Solid Tumor, Protocol Specific Less << Phase 1 Completed - United States, South Dakota ... More >> Sanford Cancer Center-Oncology Clinic Sioux Falls, South Dakota, United States, 57104 United States, Wisconsin University of Wisconsin Hospital and Clinics Madison, Wisconsin, United States, 53792 Less <<
NCT00320385 Neoplasms, Breast Phase 3 Completed - -
NCT00258050 Neoplasms, Breast Phase 1 Completed - United States, New Hampshire ... More >> GSK Investigational Site Lebanon, New Hampshire, United States, 03756 United States, North Carolina GSK Investigational Site Chapel Hill, North Carolina, United States, 27599 Less <<
NCT00320385 - Completed - -
NCT01434303 HER2/Neu Positive ... More >> Invasive Breast Carcinoma Recurrent Breast Carcinoma Stage IV Breast Cancer AJCC v6 and v7 Less << Phase 1 Active, not recruiting - United States, Texas ... More >> M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00709618 Neoplasms, Breast Phase 2 Terminated(Evolving standard o... More >>f care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.) Less << - -
NCT01495884 Her2 Positive Metastatic Breas... More >>t Cancer Less << Phase 1 Phase 2 Terminated(Slower than anticip... More >>ated accrual) Less << - Ireland ... More >> Bon Secours Hospital Cork, Ireland Cork University Hospital Cork, Ireland Beaumont Hospital Dublin, Ireland Mater Misercordiae University Hospital Dublin, Ireland Mater Private Hospital Dublin, Ireland St James's Hospital Dublin, Ireland St. Vincent's University Hospital Dublin, Ireland University Hospital Galway Galway, Ireland University Hospital Limerick Limerick, Ireland Waterford Regional Hospital Waterford, Ireland Less <<
NCT02230553 Colorectal Cancer Phase 1 Phase 2 Recruiting December 2019 Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066CX Contact: N HM Steeghs, MD, PhD    0031205122446    n.steeghs@nki.nl Less <<
NCT00486954 Neoplasms, Gastrointestinal Tr... More >>act Less << Phase 3 Completed - China, Guangdong ... More >> GSK Investigational Site Guangzhou, Guangdong, China, 510060 China GSK Investigational Site Beijing, China, 100021 GSK Investigational Site Beijing, China, 100071 GSK Investigational Site Shanghai, China, 200032 Japan GSK Investigational Site Tokyo, Japan, 113-8677 Korea, Republic of GSK Investigational Site Hwasun, Korea, Republic of, 519-809 GSK Investigational Site Seongnam-si Gyeonggi-do, Korea, Republic of, 463-707 GSK Investigational Site Seoul, Korea, Republic of, 110-744 GSK Investigational Site Seoul, Korea, Republic of, 120-752 GSK Investigational Site Seoul, Korea, Republic of, 135-710 Taiwan GSK Investigational Site Kaohsiung, Taiwan, 807 GSK Investigational Site Niaosong Township, Kaohsiung, Taiwan, 833 GSK Investigational Site Tainan County, Taiwan, 736 GSK Investigational Site Tainan, Taiwan, 704 GSK Investigational Site Taipei, Taiwan, 100 GSK Investigational Site Taipei, Taiwan, 112 GSK Investigational Site Tau-Yuan County, Taiwan, 333 Less <<
NCT00975988 - Completed - Korea, Republic of ... More >> GSK Investigational Site Seoul, Korea, Republic of, 110-744 GSK Investigational Site Seoul, Korea, Republic of, 134-701 Less <<
NCT00486954 - Completed - -
NCT00206427 - Completed - -
NCT01145404 GastroEsophageal Cancer Phase 2 Terminated(Changes of SoC for ... More >>third line therapy resulting in poor recruitment) Less << - Germany ... More >> CHARITÉ CAMPUS, VIRCHOW-KLINIKUM, UNIVERSITÄTSMEDIZIN BERLIN, Centrum 14, Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie Berlin, Germany, 13353 Evangelisches Krankenhaus Bielefeld gGmbH, Klinik für Innere Medizin, Hämatologie/Onkologie und Palliativmedizin Bielefeld, Germany, 33611 Medizinische Uniklinik, Knappschaftskrankenhaus Bochum Bochum, Germany, 44892 Evangelische Kliniken Bonn gGmbH, Johanniter-Krankenhaus Bonn, Germany, 53113 Städtisches Klinikum Braunschweig gGmbH Braunschweig, Germany, 38114 Kliniken Essen Mitte, Department of Medical Oncology and Hematology Essen, Germany, 45136 Klinikum Esslingen, Klinik für Allgemeine Innere Medizin, Onkologie und Gastroenterologie Esslingen, Germany, 73730 Krankenhaus Nord West Frankfurt, Germany, 60488 Universitätsklinikum Halle, Klinik für Innere Medizin IV Halle, Germany, 06120 OncoResearch Lerchenfeld UG Hamburg, Germany, 22081 Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie, Endokrinologie Hannover, Germany, 30625 NCT Heidelberg Heidelberg, Germany, 69120 I. Med. Klinik und Poliklinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Germany, 55101 Universitätsklinikum Gießen und Marburg GmbH Marburg, Germany, 35043 Klinikum rechts der Isar München, Germany, 81675 Klinikum Regensburg, Klinik und Poliklinik für Innere Medizin I Regensburg, Germany, 93042 Less <<
NCT01238029 Metastatic Breast Cancer ... More >> HER2 Positive First or Second Line Therapy Failure or Contraindication of Trastuzumab Therapy Less << Phase 1 Terminated(new methods of trea... More >>tment, no more patients appilicable for study) Less << - Germany ... More >> Onkologie Ravensburg Ravensburg, Baden-Württemberg, Germany, 88214 Praxisgemeinschaft Dres. Siehl und Söling Kassel, Hessen, Germany, 34117 Onkologische Schwerpunktpraxis Goslar, Niedersachsen, Germany, 38642 Onkologische Schwerpunktpraxis Leer Emden Leer, Niedersachsen, Germany, 26789 Schwerpunktpraxis Hämatologie / Onkologie Stade, Niedersachsen, Germany, 21680 Onkodok (Dr. Rösel und Dr. Depenbusch) Guetersloh, Nordrhein-Westfalen, Germany, 33332 Praxis für Hämatologie und Onkologie Mulheim an der Ruhr, Nordrhein-Westfalen, Germany, 45468 Hämatologisch-onkologische Gemeinschaftspraxis Münster, Nordrhein-Westfalen, Germany, 48149 Praxis für Onkologie u. Hämatologie Neuss, Nordrhein-Westfalen, Germany, 41462 Onkologische Gemeinschaftspraxis Dörfel/Göhler Dresden, Saxony, Germany, 01127 Onkologische Schwerpunktpraxis Heidelberg, Germany, 69115 Less <<
NCT02362958 HER2 Positive Breast Cancer Phase 2 Recruiting December 2020 China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510080 Contact: Zhong-Yu Yuan, M.D.    86-20-87343794 Less <<
NCT00709618 - Terminated(Evolving standard o... More >>f care practices in this disease setting was limiting enrolment and leading to a delay in delivering this study information to the public.) Less << - -
NCT00470847 Breast Cancer ... More >> Brain Metastases Less << Phase 1 Completed - United States, Indiana ... More >> Indiana University Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Massachusetts Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT01275859 Breast Cancer Phase 2 Completed - Korea, Republic of ... More >> Asan Nedical Center Seoul, Korea, Republic of, 138-736 Less <<
NCT00206427 Breast Cancer Phase 2 Completed - United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, New Mexico University of New Mexico Albuquerque, New Mexico, United States, 87131 United States, Texas Baylor Breast Center Houston, Texas, United States, 77030 Less <<
NCT00849329 Neoplasms, Breast Phase 1 Completed - United States, South Carolina ... More >> GSK Investigational Site Greenville, South Carolina, United States, 29605 Korea, Republic of GSK Investigational Site Seoul, Korea, Republic of, 135-710 GSK Investigational Site Songpa-gu, Seoul, Korea, Republic of, 138-736 Spain GSK Investigational Site Hospitalet de Llobregat (Barcelona), Spain, 08907 Less <<
NCT00470847 - Completed - -
NCT00544804 Breast Cancer ... More >> Metastatic Cancer Less << Phase 1 Completed - United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 Less <<
NCT00313599 Bladder Cancer ... More >> Brain and Central Nervous System Tumors Breast Cancer Esophageal Cancer Extragonadal Germ Cell Tumor Gastric Cancer Lung Cancer Ovarian Cancer Prostate Cancer Less << Phase 1 Completed - United States, California ... More >> UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California, United States, 94115 Less <<
NCT01868503 Male Breast Cancer ... More >> Recurrent Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Less << Phase 2 Terminated(Protocol modificati... More >>on) Less << - United States, California ... More >> Stanford University Cancer Institute Stanford, California, United States, 94305 Less <<
NCT01868503 - Terminated(Protocol modificati... More >>on) Less << - -
NCT00299286 Breast Cancer Phase 2 Completed - United Kingdom ... More >> Royal Marsden NHS Foundation Trust London, United Kingdom Less <<
NCT00444535 - Active, not recruiting - -
NCT01281163 Estrogen Receptor Negative ... More >> Estrogen Receptor Positive HER2/Neu Positive Progesterone Receptor Negative Progesterone Receptor Positive Recurrent Breast Carcinoma Stage IV Breast Cancer Less << Phase 1 Terminated - United States, Connecticut ... More >> Yale University New Haven, Connecticut, United States, 06520 United States, Massachusetts Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Michigan University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States, 48109 Wayne State University/Karmanos Cancer Institute Detroit, Michigan, United States, 48201 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 Less <<
NCT00444535 Neoplasms, Breast Phase 2 Active, not recruiting December 31, 2019 United States, Arizona ... More >> Novartis Investigative Site Tucson, Arizona, United States, 85724 United States, California Novartis Investigative Site San Francisco, California, United States, 94115 United States, Florida Novartis Investigative Site Hollywood, Florida, United States, 33021 Novartis Investigative Site Tampa, Florida, United States, 33612 United States, New York Novartis Investigative Site Basking Ridge, New York, United States, 07920 Novartis Investigative Site Commack, New York, United States, 11725 Novartis Investigative Site New York, New York, United States, 10065 Novartis Investigative Site Rockville Centre, New York, United States, 11570 Novartis Investigative Site Sleepy Hollow, New York, United States, 10591 Less <<
NCT00939523 Pituitary Adenomas|Prolactinom... More >>as Less << PHASE2 COMPLETED 2025-12-18 Cedars-Sinai Medical Center, L... More >>os Angeles, California, 90048, United States|Johns Hopkins University, Baltimore, Maryland, 21287, United States|Massachusetts General Hospital, Boston, Massachusetts, 02114, United States Less <<
NCT01118975 - Terminated(Lost sponsorship fo... More >>r study drug) Less << - -
NCT01138384 Breast Cancer Phase 1 Phase 2 Completed - Canada, British Columbia ... More >> BCCA - Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Cancer Centre of Southeastern Ontario at Kingston Kingston, Ontario, Canada, K7L 5P9 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Canada, Quebec McGill University - Dept. Oncology Montreal, Quebec, Canada, H2W 1S6 Less <<
NCT01118975 Breast Cancer ... More >> Neoplasm Metastasis Less << Phase 1 Phase 2 Terminated(Lost sponsorship fo... More >>r study drug) Less << - United States, Maryland ... More >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Less <<
NCT01087983 Advanced Cancers Phase 1 Completed - United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT02650752 Metastatic Breast Cancer ... More >> Central Nervous System (CNS) Metastases Less << Phase 1 Active, not recruiting January 2020 United States, Michigan ... More >> University of Michigan Health System Ann Arbor, Michigan, United States, 48109 United States, New Jersey Memoral Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Harrison, New York, United States, 10604 Queens Cancer Center of Queens Hospital Jamaica, New York, United States, 11432 Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan Kettering at Mercy Medical Center Rockville Centre, New York, United States Less <<
NCT00169533 Neoplasms, Breast Phase 1 Completed - United States, Indiana ... More >> GSK Investigational Site Indianapolis, Indiana, United States, 46202 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48201 United States, New Hampshire GSK Investigational Site Lebanon, New Hampshire, United States, 03756 United States, New Mexico GSK Investigational Site Albuquerque, New Mexico, United States, 87131 United States, North Carolina GSK Investigational Site Chapel Hill, North Carolina, United States, 27599 GSK Investigational Site Durham, North Carolina, United States, 27705 United States, Ohio GSK Investigational Site Cleveland, Ohio, United States, 44106 United States, Pennsylvania GSK Investigational Site Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site San Antonio, Texas, United States, 78229 Canada, Alberta GSK Investigational Site Edmonton, Alberta, Canada, T6G 1Z2 Israel GSK Investigational Site Tel Aviv, Israel, 64239 Less <<
NCT01218529 Brain Metastases|Lung Tumors|B... More >>reast Tumors Less << PHASE2 COMPLETED 2025-12-14 General Hospital of Athens 'Hi... More >>ppokratio', 2nd Dept of Internal Medicine, Athens, 11527, Greece|Sotiria General Hospital, 3rd Dept of Medicine, Oncology Unit, Athens, 11527, Greece|General Peripheral Hospital of Athens "Alexandra", Athens, 11528, Greece|Agii Anargiri Cancer Hospital, 3rd Dept of Medical Oncology, Athens, 14564, Greece|Hygeia Hospital, 1st Dept of Medical Oncology, Athens, 15123, Greece|Hygeia Hospital, 2nd Dept of Medical Oncology, Athens, 15123, Greece|Metropolitan Hospital, 1st Dept of Medical Oncology, Athens, 18547, Greece|Metropolitan Hospital, 2nd Dept of Medical Oncology, Athens, 18547, Greece|Chania General Hospital, Oncology Section, Chania, 73100, Greece|Ioannina University Hospital, Dept of Medical Oncology, Ioannina, 45110, Greece|University Hospital of Larissa, Dept of Internal Medicine, Oncology Section, Larissa, 44110, Greece|Rio University Hospital, Dept of Medical Oncology, Patras, 26500, Greece|Papageorgiou General Hospital, Dept of Medical Oncology, Thessaloniki, 56429, Greece Less <<
NCT00759642 Metastatic Breast Cancer Phase 2 Active, not recruiting December 2017 United States, Kansas ... More >> University of Kansas Medical Center Kansas City, Kansas, United States, 66160 Cotton-O-Neil Cancer Center (Stormont Vail Health Care) Topeka, Kansas, United States, 66606 United States, Missouri Truman Medical Center Kansas City, Missouri, United States, 64108 Less <<
NCT00903656 Metastatic Breast Cancer Phase 2 Terminated(Caelyx was not avai... More >>lable anymore) Less << - Austria ... More >> Uniklinik Salzburg Salzburg, Austria, 5020 Less <<
NCT00246753 - Completed - -
NCT01557764 Breast Neoplasms Phase 2 Withdrawn March 2016 -
NCT01497626 Advanced Solid Tumors Phase 1 Terminated(Drug support withdr... More >>awn) Less << - United States, District of Col... More >>umbia Georgetown Lombardi Comprehensive Cancer Center Washington, District of Columbia, United States, 20007 Less <<
NCT01985893 Metastatic Breast Cancer Phase 2 Withdrawn(Due to missing patie... More >>nt recruitment, the financial support was stopped.) Less << - Germany ... More >> Charite Campus Mitte II. Medizinische Klinik Hämatologie und Onkologie Berlin, Germany, 10117 Gynäkologische Praxis Dr. Jörg Schilling Berlin, Germany, 10317 MediOnko Institut GbR Dr. Klare Berlin, Germany, 10367 Gynäkologische Praxis Dr. Ruhmland Berlin, Germany, 12683 Gynäkologische Gemeinschaftspraxis Morack/Letschert Berlin, Germany, 13156 Gynäkologische Praxis Dr. Jungberg Chemnitz, Germany, 09117 UK, Frauenheilk. u. Geburtsklinik Prof. Dr. med. Pauline Wimberger Dresden, Germany, 01307 Kliniken Essen-Mitte PD Dr. Kümmel Essen, Germany, 45136 Gynäkologische Praxis Dr. Heinrich Fürstenwalde, Germany, 15517 Gynäkologische Praxis Dr. Busch Mühlhausen, Germany, 99974 Gemeinschaftspraxis "Gynäkologie Arabella" Dr. Prechtl München, Germany, 81925 Praxis für Innere Medizin Dr. Uhlig Naunhof, Germany, 14683 Gynäkologische Praxis Dr. Guth Plauen, Germany, 08525 Gynäkologische Praxis Dr. Dietz Salzgitter, Germany, 38226 g.sund Kompetenzzentrum Dr. Hielscher Stralsund, Germany, 18435 Asklepios Kliniken Weißenfels Dr. Lampe Weißenfels, Germany, 06667 Gynäkologische Praxis Dr. Guido Augustinus Süttmann Wunstorf, Germany, 31515 Less <<
NCT00246753 Prostate Cancer Phase 2 Completed - United States, North Carolina ... More >> Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill Chapel Hill, North Carolina, United States, 27599-7295 Duke Comprehensive Cancer Center Durham, North Carolina, United States, 27710 Rex Cancer Center at Rex Hospital Raleigh, North Carolina, United States, 27607 Less <<
NCT00225758 Metastatic Breast Cancer PHASE2 TERMINATED 2025-10-11 University of Colorado Cancer ... More >>Center, Aurora, Colorado, 80045, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756, United States|North Shore University Hospital, Lake Success, New York, 11042, United States Less <<
NCT00952692 Metastatic Breast Cancer Phase 1 Phase 2 Completed - United States, North Carolina ... More >> Duke University Medical Center Durham, North Carolina, United States, 27710 Less <<
NCT00759642 - Active, not recruiting - -
NCT01730677 Metastatic Breast Cancer Phase 2 Unknown December 2017 Korea, Republic of ... More >> National Cancer Center Recruiting Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Contact: Jungsil Ro    +82-31-920-1610    jungsro@ncc.re.kr    Contact: Inhae Park    +82-31-920-1680    parkih@ncc.re.kr    Principal Investigator: Jungsil Ro Less <<
NCT02581124 Anemia of Chronic Kidney Disea... More >>se Less << Phase 1 Completed - United States, Minnesota ... More >> Minneapolis, Minnesota, United States Less <<
NCT01262469 Metastatic Breast Cancer ... More >> 70 Years Old Patients and Over After One Line of Chemotherapy With Trastuzumab Less << Phase 2 Completed - France ... More >> Centre Paul Papin Angers, France, 49933 Centre Hospitalier de Beauvais Beauvais, France, 60021 Clinique Tivoli Bordeaux, France, 33000 Ch Fleyriat Bourg-en-Bresse, France, 01012 Institut Cancérologie- CENTRE HOSPITALIER BREST Brest, France, 29200 Centre Francois Baclesse Caen, France, 14076 Centre Hospitalier de Lagny-Sur-Marne Lagny-sur-Marne, France, 77405 Centre Oscar Lambret Lille, France, 59020 Institut Paoli Calmettes Marseille, France, 13273 Centre Rene Gauducheau Nantes, France, 44805 Centre Antoine Lacassagne Nice, France, 06189 Centre Hospitalier Orleans La Source Orléans, France, 45100 Institut Curie Paris, France, 75005 Hegp-Hopital Broussais Paris, France, 75015 Polyclinique de Courlancy Reims, France, 51100 Centre Hospitalier de Roanne Roanne, France, 42328 Centre Henri Becquerel Rouen, France, 76038 Centre Rene Huguenin Saint-Cloud, France, 92210 Centre Paul Strauss Strasbourg, France, 67065 Institut Claudius Regaud Toulouse, France, 31052 Less <<
NCT00225758 Metastatic Breast Cancer PHASE2 TERMINATED 2025-10-11 University of Colorado Cancer ... More >>Center, Aurora, Colorado, 80045, United States|Norris Cotton Cancer Center, Lebanon, New Hampshire, 03756, United States|North Shore University Hospital, Lake Success, New York, 11042, United States Less <<
NCT01272141 - Terminated(Slow accrual, Fundi... More >>ng stopped) Less << - -
NCT01272141 Breast Neoplasms ... More >> Breast Cancer Cancer of the Breast Less << Phase 2 Terminated(Slow accrual, Fundi... More >>ng stopped) Less << - United States, Georgia ... More >> Grady Memorial Hospital Atlanta, Georgia, United States, 30303 Emory Midtown (Crawford Long Hospital) Atlanta, Georgia, United States, 30308 Emory University Winship Cancer Institute Atlanta, Georgia, United States, 30329 Less <<
NCT01128543 Cancer Phase 2 Completed - Turkey ... More >> GSK Investigational Site Ankara, Turkey, 06100 GSK Investigational Site Ankara, Turkey, 06500 GSK Investigational Site Ankara, Turkey, 06590 GSK Investigational Site Diskapi / Ankara, Turkey, 337088 GSK Investigational Site Diyarbakir, Turkey, 21280 GSK Investigational Site Istanbul, Turkey, 34390 GSK Investigational Site Istanbul, Turkey, 34668 GSK Investigational Site Kayseri, Turkey, 38039 Less <<
NCT01128543 - Completed - -
NCT01847599 Metastatic Breast Cancer ... More >> Colorectal Cancer Less << Not Applicable Terminated(interim analysis d... More >>iscontinuation for efficacy of the intervention) Less << - France ... More >> Centre Jean Perrin Clermont Ferrand, France, 63011 Less <<
NCT00470704 Breast Cancer Phase 2 Active, not recruiting December 2019 United States, Alabama ... More >> University fo Alabama at Birmingham Birmingham, Alabama, United States, 35294 United States, Illinois University of Chicago Chicago, Illinois, United States, 60452 United States, Massachusetts Dana-Farber at Faulkner Hospital Boston, Massachusetts, United States, 02130 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, North Carolina University of North Carolina Chapel Hill, North Carolina, United States, 27599 United States, Tennessee Vanderbilt University Nashville, Tennessee, United States, 37232 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 Less <<
NCT00359190 Neoplasms, Breast Phase 1 Completed - United States, Florida ... More >> GSK Investigational Site Miami, Florida, United States, 33136-1002 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Pennsylvania GSK Investigational Site Allentown, Pennsylvania, United States, 18104 GSK Investigational Site Pittsburgh, Pennsylvania, United States, 15213 United States, Tennessee GSK Investigational Site Nashville, Tennessee, United States, 37203 United States, Texas GSK Investigational Site Dallas, Texas, United States, 75235 United States, Virginia GSK Investigational Site Roanoke, Virginia, United States, 24018 United States, Wisconsin GSK Investigational Site Milwaukee, Wisconsin, United States, 53226 Israel GSK Investigational Site Ramat Gan, Israel, 52621 GSK Investigational Site Zrifin, Israel, 70300 Less <<
NCT01947023 BRAF V600E Mutation Present ... More >> BRAF V600K Mutation Present Metastatic Thyroid Gland Carcinoma Unresectable Thyroid Gland Carcinoma Less << Phase 1 Active, not recruiting - United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 Less <<
NCT01044485 Metastatic Breast Cancer Phase 1 Phase 2 Completed - France ... More >> Centre Georges François Leclerc Dijon, Bourgogne, France, 21000 Less <<
NCT02238509 Metastatic Breast Cancer Phase 2 Unknown October 2017 Italy ... More >> A.O.U. Ospedali Riuniti Umberto I Not yet recruiting Ancona, Italy, 60020 Contact: Stefano Cascinu, MD          Principal Investigator: Stefano Cascinu, MD          Centro di Riferimento Oncologico Recruiting Aviano, Italy, 33081 Contact: Simon Spazzapan, MD          Principal Investigator: Simon Spazzapan, Md          Policlinico S. Orsola Malpighi Not yet recruiting Bologna, Italy, MD Contact: Claudio Zamagni, MD          Principal Investigator: Claudio Zamagni, MD          Ospedale Centrale di Bolzano Not yet recruiting Bolzano, Italy, 39100 Contact: Elisabetta Cretella, MD          Principal Investigator: Elisabetta Cretella, MD          Presidio Ospedaliero `Antonio Perrino Recruiting Brindisi, Italy, 72100 Contact: Saverio Cinieri, MD          Principal Investigator: Saverio Cinieri, MD          A.O.R.N.A.S. Garibaldi Nesima di Catania Recruiting Catania, Italy, 95122 Contact: Roberto Bordonaro, MD          Principal Investigator: Roberto Bordonaro, MD          Humanitas Centro Catanese di Oncologia Not yet recruiting Catania, Italy, 95126 Contact: Michele Caruso, MD          Principal Investigator: Michele Caruso, MD          Azienda Ospedaliera S. Anna Not yet recruiting Como, Italy, 22100 Contact: Monica Giordano, MD          Principal Investigator: Monica Giordano, MD          Ospedale `F. Spaziani` Not yet recruiting Frosinone, Italy, 03100 Contact: Teresa Gamucci, MD          Principal Investigator: Teresa Gamucci, MD          I.R.C.C.S. A.O.U. San Martino Not yet recruiting Genova, Italy, 16132 Contact: Lucia Del Mastro, MD          Principal Investigator: Lucia Del Mastro, MD          Ospedale Civile di Guastalla Not yet recruiting Guastalla, Italy, 42016 Contact: Laura Scaltriti, Md          Principal Investigator: Laura Scaltriti, Md          Ospedale Vito Fazzi Recruiting Lecce, Italy, 73100 Contact: Mariangela Ciccarese, MD          Principal Investigator: Mariangela Ciccarese, MD          Ospedale di Lugo - AUSL della Romagna Not yet recruiting Lugo, Italy, 48022 Contact: Michele Gianni Turolla, MD          Principal Investigator: Michele Gianni Turolla, Md          Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori Not yet recruiting Meldola, Italy, 47014 Contact: Dino Amadori, MD          Principal Investigator: Dino Amadori, MD          Ospedale Niguarda Ca' Granda Not yet recruiting Milano, Italy, 20162 Contact: Salvatore Siena, Md          Principal Investigator: Salvatore Siena, Md          A.O. San Gerardo Recruiting Monza, Italy, 20900 Contact: Marina Elena Cazzaniga, MD    039-233.3683    ricercaindipendente.monza@gmail.com    Principal Investigator: Marina Elena Cazzaniga, MD          AORN "A. Cardarelli" Recruiting Naples, Italy, 80131 Contact: Nando Riccardi, MD    08174721740    nando.riccardi@alice.it    Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale" Recruiting Napoli, Italy, 8011 Contact: Michele De Laurentiis, MD          Principal Investigator: Michele De Laurentiis, MD          Policlinico SUN Not yet recruiting Napoli, Italy, 80131 Contact: Michele Orditura, MD          Principal Investigator: Michele Orditura, MD          Università degli Studi di Napoli "Federico II" Recruiting Napoli, Italy, 80131 Contact: Grazia Arpino, MD          Principal Investigator: Grazia Arpino, MD          A.R.N.A.S. Ospedale Civico e Benfratelli Recruiting Palermo, Italy, 90127 Contact: Vita Leonardi, MD          Principal Investigator: Vita Leonardi, MD          Ospedale S. Maria della Misericordia Recruiting Perugia, Italy, 06156 Contact: Anna Maria Mosconi, MD          Principal Investigator: Anna Maria Mosconi, MD          Azienda Ospedaliera Santa Maria degli Angeli Not yet recruiting Pordenone, Italy, 33170 Contact: Silvana Saracchini, MD          Principal Investigator: Silvana Saracchini, MD          Ospedale di Ravenna Not yet recruiting Ravenna, Italy, 48100 Contact: Claudio Dazzi, MD          Principal Investigator: Dazzi Claudio, MD          Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia Not yet recruiting Reggio Emilia, Italy, 42123 Contact: Corrado Boni, MD          Principal Investigator: Corrado Boni, MD          Ospedale Infermi di Rimini Not yet recruiting Rimini, Italy, 47923 Contact: Lorenzo Gianni, MD          Principal Investigator: Lorenzo Gianni, MD          Policlinico Universitario Campus Biomedico Recruiting Roma, Italy, 00128 Contact: Giuseppe Tonini, Md          Principal Investigator: Giuseppe Tonini, MD          Istituto Regina Elena per lo studio e la cura dei tumori Recruiting Roma, Italy, 00144 Contact: Francesco Cognetti, Md          Principal Investigator: Cognetti Francesco, MD          Ospedale G. Da Procida Not yet recruiting Salerno, Italy, 84126 Contact: Maria Luisa Barzelloni, MD          Principal Investigator: Maria Luisa Barzelloni, MD          Ospedale Civile di Sassari SS Annunaziata Recruiting Sassari, Italy, 07100 Contact: Nina Olmeo, MD          Principal Investigator: Nina Olmeo, MD          Ospedale `SS. Trinità` Recruiting Sora, Italy, 03039 Contact: Teresa Gamucci, MD          Principal Investigator: Teresa Gamucci, MD          Azienda Ospedaliera S.Maria di Terni Recruiting Terni, Italy, 05100 Contact: Fauso Roila, Md          Principal Investigator: Fausto Roila, MD          A.O.U. San Giovanni Battista di Torino Not yet recruiting Torino, Italy, 10126 Contact: Mario Airoldi, MD          Principal Investigator: Mario Airoldi, MD          A.O.U. Santa Maria della Misericordia di Udine Recruiting Udine, Italy, 33100 Contact: fabio Puglisi, MD          Principal Investigator: Fabio Puglisi, MD          A.O. Ospedale di Circolo e Fondazione Macchi Not yet recruiting Varese, Italy, 21100 Contact: Giovanni Giardina, MD          Principal Investigator: Giovanni Giardina, MD          Ospedale Sacro Cuore Don Calabria Not yet recruiting Verona, Italy, 37024 Contact: Stefania Gori, MD          Principal Investigator: Stefania Gori, MD Less <<
NCT01133912 Breast Cancer Phase 1 Completed - Korea, Republic of ... More >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 Less <<
NCT00881621 - Terminated(slow enrollment) - -
NCT00528281 Lung Cancer, Non-Small Cell Phase 1 Completed - Germany ... More >> GSK Investigational Site Heidelberg, Baden-Wuerttemberg, Germany, 69126 GSK Investigational Site Grosshansdorf, Schleswig-Holstein, Germany, 22927 Italy GSK Investigational Site Orbassano (TO), Piemonte, Italy, 10043 Poland GSK Investigational Site Poznan, Poland, 60-569 United Kingdom GSK Investigational Site Newcastle upon Tyne, United Kingdom, NE7 7DN Less <<
NCT00721630 - Completed - -
NCT00881621 Pancreas Cancer Phase 2 Terminated(slow enrollment) - United States, District of Col... More >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 Less <<
NCT00721630 Breast Cancer Phase 2 Completed - United States, New Jersey ... More >> Memorial Sloan-Kettering at Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan-Kettering Cancer Center at Commack Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Memorial Sloan-Kettering Cancer Center at Mercy Medical Center Rockville Centre, New York, United States, 11570 Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow, New York, United States, 10591 Less <<
NCT00984425 Solid Tumors Phase 1 Completed - Italy ... More >> Istituto Clinco Humanitas Rozzano, Milano, Italy, 20089 Less <<
NCT00496366 - Terminated - -
NCT01591577 Newly Diagnosed Glioblastoma M... More >>ultiforme Less << Phase 2 Recruiting December 7, 2019 United States, California ... More >> UCLA Recruiting Los Angeles, California, United States, 90095 Principal Investigator: Pioanh Nghiemphu, MD Less <<
NCT00496366 Breast Cancer ... More >> Metastatic Breast Cancer Advanced Breast Cancer HER2/Neu-positive Breast Cancer Less << Phase 2 Terminated - United States, New Jersey ... More >> Rutgers Cancer Institute of New Jersey at Hamilton Hamilton, New Jersey, United States, 08690 Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 Less <<
NCT00996762 Neoplasms, Breast Phase 1 Completed - United States, Arizona ... More >> GSK Investigational Site Scottsdale, Arizona, United States, 85259 GSK Investigational Site Tucson, Arizona, United States, 85724 United States, District of Columbia GSK Investigational Site Washington, District of Columbia, United States, 20007 United States, Florida GSK Investigational Site Fort Myers, Florida, United States, 33905 United States, Georgia GSK Investigational Site Atlanta, Georgia, United States, 30341 United States, Michigan GSK Investigational Site Detroit, Michigan, United States, 48202 United States, Tennessee GSK Investigational Site Memphis, Tennessee, United States, 38120 GSK Investigational Site Nashville, Tennessee, United States, 37203 Korea, Republic of GSK Investigational Site Seoul, Korea, Republic of, 120-752 Less <<
NCT01700010 Urothelial Cancer ... More >> Bladder Cancer Less << Phase 2 Withdrawn(Funding issues.) January 2019 United States, Michigan ... More >> University of Michigan Ann Arbor, Michigan, United States, 48109 Less <<
NCT00614978 Metastatic Breast Cancer ... More >> Brain Metastases HER2 Positive Less << Phase 1 Completed - Belgium ... More >> Jules Bordet Institute Brussels, Belgium, 1000 Less <<
NCT01499160 - Terminated(low accrual) - -
NCT01499160 Breast Neoplasms ... More >> Endocrine Breast Diseases Neoplasm Metastasis Less << Phase 2 Terminated(low accrual) - United States, Maryland ... More >> University of Maryland Marlene & Stewart Greenebaum Cancer Center Baltimore, Maryland, United States, 21201 Less <<
NCT01264081 Malignant Melanoma PHASE2 TERMINATED 2013-11-22 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00973739 Neurofibromatosis 2|Vestibular... More >> Schwannoma Less << PHASE2 COMPLETED 2025-11-12 New York University School of ... More >>Medicine, New York, New York, 10016, United States Less <<
NCT01264081 Malignant Melanoma PHASE2 TERMINATED 2013-11-22 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT03085368 HER2-positive Breast Cancer Phase 2 Phase 3 Recruiting March 1, 2021 China ... More >> PUMCH Recruiting Beijing, China, 100730 Contact: Sun Qiang, M.D.    0086-13001289600    1210548954@qq.com    Contact: Wang Xuefei Less <<
NCT00912275 Metastatic Breast Cancer Phase 1 Phase 2 Unknown December 2013 Taiwan ... More >> Department of Oncology,National Taiwan University Hospital Recruiting Taipei, Taiwan, 100 Contact: Yen-Shen Lu, M.D.,Ph.D    886-2-23123456 ext 7787    yslu@ntu.edu.tw    Contact: Ching-Hung Lin, M.D.    886-2-23123456 ext 7513    chinghlin@ntu.edu.tw    Principal Investigator: Yen-Shen Lu, M.D.,Ph.D          Sub-Investigator: Ching-Hung Lin, M.D.          Sub-Investigator: Ching-Jin Chung, M.D.,Ph.D          Sub-Investigator: Chiun-Sheng Huang, M.D.,Ph.D Less <<
NCT00820924 Neoplasms, Breast Phase 2 Terminated - Italy ... More >> GSK Investigational Site Rimini, Emilia-Romagna, Italy, 47900 GSK Investigational Site Udine, Friuli-Venezia-Giulia, Italy, 33100 GSK Investigational Site Bergamo, Lombardia, Italy, 24128 GSK Investigational Site Milano, Lombardia, Italy, 20121 GSK Investigational Site Rozzano (MI), Lombardia, Italy, 20089 GSK Investigational Site Livorno, Toscana, Italy, 57124 GSK Investigational Site Prato (PO), Toscana, Italy, 59100 GSK Investigational Site Perugia, Umbria, Italy, 06156 GSK Investigational Site Ancona, Italy, 60020 United Kingdom GSK Investigational Site London, United Kingdom, W6 8RF Less <<
NCT01427322 Epithelial Cancer Early Phase 1 Terminated(Slow accrual) - United States, Virginia ... More >> Hunter Holmes McGuire VA Medical Center Richmond, Virginia, United States, 23249 Massey Cancer Center, Virginia Commonwealth University Richmond, Virginia, United States, 23298-0037 Less <<
NCT00694252 Metastatic Breast Cancer PHASE2 COMPLETED 2025-11-11 University Hospital of Crete, ... More >>Heraklion, 71110, Greece Less <<
NCT00650910 Neoplasms, Breast Phase 1 Completed - United States, New Mexico ... More >> GSK Investigational Site Albuquerque, New Mexico, United States, 87131 Canada, Alberta GSK Investigational Site Edmonton, Alberta, Canada, T6G 1Z2 Korea, Republic of GSK Investigational Site Seodaemun-gu, Seoul, Korea, Republic of, 120-752 GSK Investigational Site Seoul, Korea, Republic of, 110-744 Less <<
NCT00973739 Neurofibromatosis 2|Vestibular... More >> Schwannoma Less << PHASE2 COMPLETED 2025-11-12 New York University School of ... More >>Medicine, New York, New York, 10016, United States Less <<
NCT00857714 Ductal Carcinoma in Situ Not Applicable Terminated(Terminated due to l... More >>ow accrual) Less << - United States, Indiana ... More >> Indiana University Indianapolis, Indiana, United States, 46202 Less <<
NCT03075995 Breast Cancer Not Applicable Recruiting April 1, 2019 China, Guangdong ... More >> Sun Yat-sen University Cancer Center Recruiting Guangzhou, Guangdong, China, 510000 Contact: Fei Xu, Degree    87342693    xufei@sysucc.org.cn Less <<
NCT00857714 - Terminated(Terminated due to l... More >>ow accrual) Less << - -
NCT02342587 HER2-positive Refractory Advan... More >>ced Cancer Less << PHASE2 COMPLETED 2016-08-21 Samsung Medical Center, Seoul,... More >> Korea, Republic of Less <<
NCT02101905 Anaplastic Astrocytoma ... More >> Anaplastic Ependymoma Anaplastic Oligodendroglioma Gliosarcoma Mixed Glioma Recurrent Adult Brain Neoplasm Recurrent Glioblastoma Less << Phase 1 Recruiting - United States, California ... More >> UCLA / Jonsson Comprehensive Cancer Center Suspended Los Angeles, California, United States, 90095 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Suspended Baltimore, Maryland, United States, 21287 United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact    877-442-3324       Principal Investigator: Eudocia Q. Lee          United States, Michigan Henry Ford Hospital Recruiting Detroit, Michigan, United States, 48202 Contact: Site Public Contact    313-916-1784       Principal Investigator: Tobias Walbert          United States, New Jersey Memorial Sloan Kettering Basking Ridge Suspended Basking Ridge, New Jersey, United States, 07920 Memorial Sloan Kettering Monmouth Suspended Middletown, New Jersey, United States, 07748 United States, New York Memorial Sloan Kettering Commack Suspended Commack, New York, United States, 11725 Memorial Sloan Kettering Westchester Suspended Harrison, New York, United States, 10604 Memorial Sloan Kettering Cancer Center Suspended New York, New York, United States, 10065 United States, North Carolina Wake Forest University Health Sciences Recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Site Public Contact    336-713-6771       Principal Investigator: Glenn J. Lesser          United States, Ohio Cleveland Clinic Foundation Suspended Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact    412-647-8073       Principal Investigator: Frank S. Lieberman Less <<
NCT01245660 Bladder Carcinoma ... More >> Infiltrative Bladder Carcinoma Cystectomy Less << Early Phase 1 Terminated(The rythm of enroll... More >>ment was not compatible with the objective of recruitement in the research.) Less << - France ... More >> CHU Bordeaux - Hôpital Saint André - Department of Medical Oncology Bordeaux, France, 33075 Less <<
NCT00863122 Vestibular Schwannoma ... More >> NF2 Neurofibromatosis 2 Acoustic Neuroma Auditory Tumor Less << Early Phase 1 Completed - United States, California ... More >> House Reserach Institute Los Angeles, California, United States, 90057 United States, Maryland Johns Hopkins Hospital Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Boston, Massachusetts, United States, 02114 United States, Missouri Washington University Medical Center Saint Louis, Missouri, United States, 63110 United States, New York New York University Medical Center New York, New York, United States, 10016 Weil Cornell Medical College, New York Presbyterian Hospital New York, New York, United States, 10065 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 Less <<
NCT00863122 - Completed - -
NCT01328054 - Completed - -
NCT01589861 Breast Cancer Phase 1 Phase 2 Suspended(Data analysis) January 2018 France ... More >> Institut Paoli-Calmettes Marseille, France, 13008 Less <<
NCT01328054 Cancer Phase 4 Completed - United States, Michigan ... More >> GSK Investigational Site Detroit, Michigan, United States, 48202 United States, New Hampshire GSK Investigational Site Lebanon, New Hampshire, United States, 03756 United States, North Carolina GSK Investigational Site Durham, North Carolina, United States, 27710 United States, Utah GSK Investigational Site Salt Lake City, Utah, United States, 84112 Less <<
NCT01934894 Metastatic Breast Cancer With ... More >>Intracranial Metastases Less << Phase 2 Terminated(Study was terminate... More >>d due to lack of significant signal of efficacy) Less << - United States, Florida ... More >> Florida Cancer Specialists - South Fort Myers, Florida, United States, 33916 Florida Cancer Specialists-North Saint Petersburg, Florida, United States, 33705 United States, Ohio Oncology Hematology Care Inc. Cincinnati, Ohio, United States, 45242 United States, Tennessee Tennessee Oncology Nashville, Tennessee, United States, 37203 Less <<
NCT01290354 Cancer Phase 1 Completed - United Kingdom ... More >> GSK Investigational Site London, United Kingdom, EC1A 7BE GSK Investigational Site London, United Kingdom, W12 0NN GSK Investigational Site London, United Kingdom, W6 8RF Less <<
NCT01283789 Metastatic Breast Cancer Phase 2 Active, not recruiting April 2017 United States, Kansas ... More >> University of Kansas Medical Centner Kansas City, Kansas, United States, 66160 Less <<
NCT01934894 - Terminated(Study was terminate... More >>d due to lack of significant signal of efficacy) Less << - -
NCT02015169 HER2-positive Gastric Cancer P... More >>atients With Liver Metastasis Less << PHASE2 COMPLETED 2017-11-17 Samsung Medical Center, Seoul,... More >> Korea, 135-720, Korea, Republic of Less <<
NCT01454479 Recurrent Endometrial Cancer Phase 1 Unknown April 2014 -
NCT01184482 Colorectal Cancer ... More >> Lung Cancer Head and Neck Cancer Less << Phase 1 Completed - United States, District of Col... More >>umbia Georgetown University Medical Center Washington, District of Columbia, United States, 20007 Less <<
NCT02158507 Metastatic Triple Negative Bre... More >>ast Cancer Less << Not Applicable Active, not recruiting September 1, 2020 United States, Alabama ... More >> University of Alabama at Birmingham Birmingham, Alabama, United States, 35294 Less <<
NCT02131506 HER-2 Positive Breast Cancer ... More >> Malignant Neoplasm of Breast Less << Phase 1 Terminated(Safety reasons) - Italy ... More >> UO Oncologia medica, IRCCS IRST Meldola, FC, Italy, 47014 Less <<
NCT01332396 Cancer COMPLETED 2017-03-13 -
NCT00239200 Metastatic or Recurrent Squamo... More >>us Cell Carcinoma of the Esophagus Less << PHASE2 TERMINATED 2025-09-07 University of Michigan Compreh... More >>ensive Cancer Center, Ann Arbor, Michigan, 48109, United States Less <<
NCT01666431 Squamous Cell Carcinoma PHASE2 TERMINATED 2025-11-13 University Hospital Zurich, Di... More >>vision of Dermatology, Zurich, ZH, 8091, Switzerland Less <<
NCT00343759 Breast Cancer PHASE2 WITHDRAWN 2025-12-09 Abramson Cancer Center of Univ... More >>ersity of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT00821054 Neoplasms, Breast PHASE1 COMPLETED 2011-03-22 GSK Investigational Site, Buff... More >>alo, New York, 14263, United States|GSK Investigational Site, Greenville, South Carolina, 29605, United States|GSK Investigational Site, Edmonton, Alberta, T6G 1Z2, Canada|GSK Investigational Site, Montreal, Quebec, H2W 1T8, Canada|GSK Investigational Site, Amsterdam, 1066 CX, Netherlands Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.60mL

1.72mL

0.86mL

17.21mL

3.44mL

1.72mL

References

 

Historical Records

Categories